Cannabinoid derivatives and their use

ABSTRACT

Provided herein are methods of using a compound of Formula (I) or pharmaceutically acceptable salt thereof, for example, in the treatment of a mental health disorder or chronic inflammatory disease.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims priority to U.S. Provisional Application No. 63/229,442 filed on Aug. 4, 2021, the contents of which is hereby incorporated by reference in its entirety for all purposes.

BACKGROUND

Cannabis plants contain various substances of medicinal interest, called cannabinoids, such as Δ9-tetrahydrocannabinol (D9-THC), A8-tetrahydrocannabinol (D8-THC), tetrahydrocannabinol acid (THC-A), tetrahydrocannabivarin (THCV), tetrahydrocannabivarin acid (THCV-A), cannabidiol (CBD), cannabidiol acid (CBD-A), cannabicromene (CBC), cannabidivarine (CBDV), canabidivine (CBDV)-A), cannabigerol (CBG), cannabigerol acid (CBG-A), cannabigerovarin (CBGV), cannabinol (CBN), cannabinovarin (CBNV), among others.

Their use has been intensively investigated for the treatment of epilepsy, nausea, vomiting, lack of appetite, pain and inflammatory diseases, and mental health disorders among other conditions.

Cannabinoids are primarily metabolized in the liver, especially by cytochrome P450 mixed-function oxidases. For example, CBD is extensively metabolized by the liver via CYP450 enzymes and the UGT enzymes. The major CYP450 isoforms responsible for the phase I metabolism of CBD are CYP2C19 and CYP3A4. The UGT isoforms responsible for the phase II conjugation of CBD are UGT1A7, UGT1A9 and UGT2B7.

There is a need for cannabinoid derivatives with increased bioavailability, especially oral bioavailability, and more efficient drug delivery and compositions and uses thereof for the treatment of various diseases or disorders, such as autoimmune diseases, chronic inflammatory diseases and mental health disorders. The need for increased oral bioavailability is evidenced by the oral dose levels and liver monitoring recommendations for Epidiolex (CBD), approved in the US in 2018 for the treatment of epilepsy disorders Lennox-Gastaut or Dravet syndrome. The typical oral dose is 2.5 mg/kg twice daily, which can be increased based upon tolerance and effect to 5 mg/kg twice daily and to a maximum of 10 mg/kg twice daily. There are numerous dose related side effects, hepatotoxicity markers are commonly elevated including 13% of patients exhibiting 3× or more the upper limit of normal (ULN) in prelicensure studies for Epidiolex®. The present invention discloses derivatives of cannabinoids that enhance oral bioavailability and efficacy in animal models compared to the natural cannabinoid molecule.

SUMMARY

In embodiments, the present disclosure relates to cannabinoid derivatives, such as alkylated derivatives of CBG and CBD, as well as pharmaceutical compositions thereof and uses thereof in treating various diseases and disorders.

In embodiments, the present disclosure provides a method of treating a chronic inflammatory disease, cancer, or mental health disorder in a subject in need thereof, comprising administering a compound of Formula (I), or a pharmaceutically acceptable salt thereof

wherein:

R¹ and R³ are independently a hydrogen, alkyl, alkyl-OH, or alkenyl; provided that at least one of R¹ and R³ is not hydrogen;

R² is

R^(E) is hydroxy, halo, —NR^(A)R^(B), cyano, nitro, alkyl, -haloalkyl, haloalkoxy or alkoxy;

R⁴, R^(4′), R⁵, R^(5′), R⁶, R^(6′), R⁷, R^(7′), R⁸, R^(8′), R⁹ are each independently selected from the group consisting of hydrogen, —OH, alkyl, alkoxy, —NR^(A)R^(B), and halogen;

R^(A) and R^(B) are each independently hydrogen or -alkyl; and

n is 0, 1, or 2.

In embodiments of the methods of the present disclosure, the compound of Formula (I) is a compound of Formula (II):

wherein the variables (i.e., R¹, R^(E), n, R³, R⁴, R^(4′), R⁵, R^(5′), R⁶, R^(6′), R⁷, R^(7′), R⁸, R^(8′), and R⁹ are defined herein.

In embodiments of the methods of the present disclosure, the compound of Formula (I) is a compound of Formula (III):

wherein the variables (i.e., R¹, R^(E), n, R³, R⁴, R^(4′), R⁵, R^(5′), R⁶, R^(6′), R⁷, R^(7′), R⁸, R^(8′), and R⁹ are defined herein.

In embodiments, the present disclosure provides a method of treating a chronic inflammatory disease, cancer, or mental health disorder in a subject in need thereof, comprising administering a compound selected from the group consisting of

In embodiments, provided herein is pharmaceutical composition comprising a compound of Formula (I):

or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

In embodiments, the present disclosure provides a method of treating a mental health disorder in a subject in need thereof, comprising administering a compound of the present disclosure (e.g., a compound of Formula (I)), or a pharmaceutical composition comprising a compound of the present disclosure.

In embodiments, the present disclosure provides a method of treating a chronic inflammatory disease in a subject in need thereof, comprising administering a compound of the present disclosure (e.g., a compound of Formula (I)), or a pharmaceutical composition comprising a compound of the present disclosure.

In embodiments, the present disclosure provides one or more compounds described in Table 1.

In embodiments, the present disclosure provides a pharmaceutical composition comprising one or more compounds described in Table 1, and a pharmaceutically acceptable carrier.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows a ¹H NMR (CDCl₃) spectrum of Compound 1.

FIG. 2 shows a ¹³C NMR (CDCl₃) spectrum of Compound 1.

FIG. 3 shows a ¹H NMR (CDCl₃) spectrum of Compound 2.

FIG. 4 shows a ¹³C NMR (CDCl₃) spectrum of Compound 2.

FIG. 5 is a graph showing Group 1 CBG Plasma Concentration vs Time Profile from the PK study described in Example 5.

FIG. 6 is a graph showing Group 1 CBG-glucuronide Plasma Concentration vs Time Profile from the PK study described in Example 5.

FIG. 7 is a graph showing Group 2 Compound 1 Plasma Concentration vs Time Profile from the PK study described in Example 5.

FIG. 8 is a graph showing Group 2 Compound 1 glucuronide Plasma Concentration vs Time Profile from the PK study described in Example 5.

FIG. 9 is a graph showing Group 3 Compound 2 Plasma Concentration vs Time Profile from the PK study described in Example 5.

FIG. 10 shows Group 3 Compound 2 glucuronide Plasma Concentration vs Time Profile from the PK study described in Example 5.

FIG. 11 is a graph showing Group 4 CBG Plasma Concentration vs Time Profile from the PK study described in Example 5.

FIG. 12 is a graph showing Group 4 CBG-glucuronide Plasma Concentration vs Time Profile from the PK study described in Example 5.

FIG. 13 shows a summary of metabolites M1-M6 of CBG in hepatocyte stability assay samples.

FIG. 14 shows a summary of metabolites M7-M12 of CBG in hepatocyte stability assay samples.

FIGS. 15A-C show graphs representing serum concentrations (pg/mL) of (A) IL-1β, (B) INFγ, and (C) TNFα pro-inflammatory cytokines following Cyclosporine A, CBG, Compound 1 or Compound 2 administration in rat LPS model.

FIG. 16 shows body weight change from Study Day −3 in rats administered compound 1 compared to positive control dexamethasone, vehicle and normal rats in the study described in Example 7.

FIG. 17 shows small intestine weight in rats administered compound 1 compared to positive control dexamethasone, vehicle and normal rats in the study described in Example 7.

FIG. 18 shows lower small intestine gross score in rats administered compound 1 compared to positive control dexamethasone, vehicle and normal rats in the study described in Example 7.

FIG. 19 shows histopathology scores in rats administered compound 1 compared to positive control dexamethasone, vehicle and normal rats in the study described in Example 7.

FIG. 20 shows necrosis width in rats administered compound 1 compared to positive control dexamethasone, vehicle and normal rats in the study described in Example 7.

FIG. 21 shows body weight change from Study Day −3 in rats administered compound 2 compared to positive control dexamethasone, vehicle and normal rats in the study described in Example 7.

FIG. 22 shows small intestine weight in rats administered compound 2 compared to positive control dexamethasone, vehicle and normal rats in the study described in Example 7.

FIG. 23 shows lower small intestine gross score in rats administered compound 2 compared to positive control dexamethasone, vehicle and normal rats in the study described in Example 7.

FIG. 24 shows histopathology scores in rats administered compound 2 compared to positive control dexamethasone, vehicle and normal rats in the study described in Example 7.

FIG. 25 shows necrosis width in rats administered compound 2 compared to positive control dexamethasone, vehicle and normal rats in the study described in Example 7.

FIG. 26 Clonogenic assay of colon cancer cell lines treated with CBG, Compound 1 and Compound 2. Representative images from three independent experiments.

FIG. 27A, FIG. 27B, FIG. 27C, and FIG. 27D show Western blot for p-cMyc(S62), cMyc, p-AKT(S473), AKT, p-ERK(T202/Y204), and ERK normalized to Vinculin in SW620, HCT15, and HCT116 cells treated with CBG, Compound 1, and Compound 2 at indicated concentrations for 3 hours.

FIG. 28 is a graph showing latency to First Seizure Event in the study described in Example 9.

FIG. 29 is a graph showing latency to Clonic Seizure Event in the study described in Example 9.

FIG. 30 . is a graph showing latency to Tonic Seizure Event in the study described in Example 9.

FIG. 31 is a graph showing Racine scores over 5 minute intervals for 30 minutes in the study described in Example 9.

FIG. 32 is a graph showing percent of animals reaching Tonic-clonic Stage 6 in the study described in Example 9.

FIG. 33 is a graph showing survival effects in the study described in Example 9.

FIG. 34 is a graph depicting the stability of CBG in the presence of UGT1A9.

FIG. 35 is a graph depicting the stability of Compound 1 in the presence of UGT1A9.

FIG. 36 shows a ¹H NMR spectrum of Compound 3.

FIG. 37 is a graph showing the effect of incubation time and protein concentration on the metabolism of CBG in UGT2B7.

FIG. 38 is a graph showing the effect of incubation time and protein concentration on the metabolism of CBG in UGT1A9.

FIG. 39 shows a ¹H NMR spectrum of Compound 14.

FIG. 40 shows a ¹H NMR spectrum of Compound 16.

FIG. 41 shows a ¹H NMR spectrum of Compound 17.

FIG. 42 shows a ¹H NMR spectrum of Compound 18.

FIG. 43 shows a ¹H NMR spectrum of Compound 19.

DEFINITIONS

Throughout this disclosure, various patents, patent applications and publications are referenced. The disclosures of these patents, patent applications and publications in their entireties are incorporated into this disclosure by reference for all purposes in order to more fully describe the state of the art as known to those skilled therein as of the date of this disclosure. This disclosure will govern in the instance that there is any inconsistency between the patents, patent applications and publications cited and this disclosure.

For convenience, certain terms employed in the specification, examples and claims are collected here. Unless defined otherwise, all technical and scientific terms used in this disclosure have the same meanings as commonly understood by one of ordinary skill in the art to which this disclosure belongs.

The term “about” when immediately preceding a numerical value means a range (e.g., plus or minus 10% of that value). For example, “about 50” can mean 45 to 55, “about 25,000” can mean 22,500 to 27,500, etc., unless the context of the disclosure indicates otherwise, or is inconsistent with such an interpretation. For example in a list of numerical values such as “about 49, about 50, about 55, . . . ”, “about 50” means a range extending to less than half the interval(s) between the preceding and subsequent values, e.g., more than 49.5 to less than 50.5. Furthermore, the phrases “less than about” a value or “greater than about” a value should be understood in view of the definition of the term “about” provided herein. Similarly, the term “about” when preceding a series of numerical values or a range of values (e.g., “about 10, 20, 30” or “about 10-30”) refers, respectively to all values in the series, or the endpoints of the range.

The term “pharmaceutically acceptable salts” includes both acid and base addition salts. Pharmaceutically acceptable salts include those obtained by reacting the active compound functioning as a base, with an inorganic or organic acid to form a salt, for example, salts of hydrochloric acid, sulfuric acid, phosphoric acid, methanesulfonic acid, camphorsulfonic acid, oxalic acid, maleic acid, succinic acid, citric acid, formic acid, hydrobromic acid, benzoic acid, tartaric acid, fumaric acid, salicylic acid, mandelic acid, carbonic acid, etc. Those skilled in the art will further recognize that acid addition salts may be prepared by reaction of the compounds with the appropriate inorganic or organic acid via any of a number of known methods.

As used herein, a “subject” can be a human, non-human primate, mammal, rat, mouse, cow, horse, pig, sheep, goat, dog, cat and the like.

“Mammal” includes humans and both domestic animals such as laboratory animals (e.g., mice, rats, monkeys, dogs, etc.) and household pets (e.g., cats, dogs, swine, cattle, sheep, goats, horses, rabbits), and non-domestic animals such as wildlife and the like.

The term “treating” as used herein with regard to a subject or patient, refers to improving at least one symptom of the patient's disorder. Treating can be improving, or at least partially ameliorating a disorder or an associated symptom of a disorder.

The terms “effective amount” and “therapeutically effective amount” are used interchangeably in this disclosure and refer to an amount of a compound, or a salt thereof, (or pharmaceutical composition containing the compound or salt) that, when administered to a patient, is capable of performing the intended result. The “effective amount” will vary depending on the active ingredient, the state, disorder, or condition to be treated and its severity, and the age, weight, physical condition and responsiveness of the mammal to be treated.

The term “therapeutically effective” applied to dose or amount refers to that quantity of a compound or pharmaceutical formulation that is sufficient to result in a desired clinical benefit after administration to a patient in need thereof.

The term “carrier” or “vehicle” as used interchangeably herein encompasses carriers, excipients, adjuvants, and diluents or a combination of any of the foregoing, meaning a material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material involved in carrying or transporting a pharmaceutical agent from one organ, or portion of the body, to another organ or portion of the body. In addition to the adjuvants, excipients and diluents known to one skilled in the art, the carrier includes nanoparticles of organic and inorganic nature.

When a range of values is listed, it is intended to encompass each value and sub-range within the range. For example, “C₁-C₆ alkyl” is intended to encompass C₁, C₂, C₃, C₄, C₅, C₆, C₁₋₆, C₁₋₅, C₁₋₄, C₁₋₃, C₁₋₂, C₂₋₆, C₂₋₅, C₂₋₄, C₂₋₃, C₃₋₆, C₁₋₅, C₃₋₄, C₄₋₆, C₄₋₅, and C₅₋₆ alkyl.

“Alkyl” or “alkyl group” refers to a fully saturated, straight or branched hydrocarbon chain having from one to twelve carbon atoms, and which is attached to the rest of the molecule by a single bond. Alkyls comprising any number of carbon atoms from 1 to 30 are included. For example, an alkyl comprising up to 12 carbon atoms is a C₁-C₁₂ alkyl, an alkyl comprising up to 10 carbon atoms is a C₁-C₁₀ alkyl, an alkyl comprising up to 6 carbon atoms is a C₁-C₆ alkyl and an alkyl comprising up to 5 carbon atoms is a C₁-C₅ alkyl. A C₁-C₅ alkyl includes C₅ alkyls, C₄ alkyls, C₃ alkyls, C₂ alkyls and C₁ alkyl (i.e., methyl). A C₁-C₆ alkyl includes all moieties described above for C₁-C₅ alkyls but also includes C₆ alkyls. A C₁-C₁₀ alkyl includes all moieties described above for C₁-C₅ alkyls and C₁-C₆ alkyls, but also includes C₇, C₈, C₉ and C₁₀ alkyls. Similarly, a C₁-C₃₀ alkyl includes all the foregoing moieties, but also includes C₁-C₃₀ alkyls. Non-limiting examples of C₁-C₁₂ alkyl include methyl, ethyl, n-propyl, i-propyl, sec-propyl, n-butyl, i-butyl, sec-butyl, t-butyl, n-pentyl, t-amyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, n-decyl, n-undecyl, and n-dodecyl. Unless stated otherwise specifically in the specification, an alkyl group can be optionally substituted.

As used herein, the term “halo” refers to fluoro, chloro, bromo, or iodo.

“Haloalkyl” refers to an alkyl, as defined herein, that is substituted by one or more halo radicals, e.g., trifluoromethyl, difluoromethyl, trichloromethyl, 2,2,2-trifluoroethyl, 1,2-difluoroethyl, 3-bromo-2-fluoropropyl, 1,2-dibromoethyl, and the like. Unless stated otherwise specifically in the specification, a haloalkyl group can be optionally substituted.

“Alkoxy” refers to a group of the formula —OR_(a) where R_(a) is an alkyl, alkenyl or alkynyl as defined above containing one to twelve carbon atoms. Unless stated otherwise specifically in the specification, an alkoxy group can be optionally substituted.

“Alkenyl” or “alkenyl group” refers to a straight or branched hydrocarbon chain having from two to twelve carbon atoms and having one or more carbon-carbon double bonds. Each alkenyl group is attached to the rest of the molecule by a single bond. Alkenyl group comprising any number of carbon atoms from 2 to 12 are included. An alkenyl group comprising up to 12 carbon atoms is a C₂-C₁₂ alkenyl, an alkenyl comprising up to 10 carbon atoms is a C₂-C₁₀ alkenyl, an alkenyl group comprising up to 6 carbon atoms is a C₂-C₆ alkenyl and an alkenyl comprising up to 5 carbon atoms is a C₂-C₅ alkenyl. A C₂-C₅ alkenyl includes C₅ alkenyls, C₄ alkenyls, C₃ alkenyls, and C₂ alkenyls. A C₂-C₆ alkenyl includes all moieties described above for C₂-C₅ alkenyls but also includes C₆ alkenyls. A C₂-C₁₀ alkenyl includes all moieties described above for C₂-C₅ alkenyls and C₂-C₆ alkenyls, but also includes C₇, C₈, C₉ and C₁₀ alkenyls. Similarly, a C₂-C₁₂ alkenyl includes all the foregoing moieties, but also includes C₁₁ and C₁₂ alkenyls. Non-limiting examples of C₂-C₁₂ alkenyl include ethenyl (vinyl), 1-propenyl, 2-propenyl (allyl), iso-propenyl, 2-methyl-1-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 1-heptenyl, 2-heptenyl, 3-heptenyl, 4-heptenyl, 5-heptenyl, 6-heptenyl, 1-octenyl, 2-octenyl, 3-octenyl, 4-octenyl, 5-octenyl, 6-octenyl, 7-octenyl, 1-nonenyl, 2-nonenyl, 3-nonenyl, 4-nonenyl, 5-nonenyl, 6-nonenyl, 7-nonenyl, 8-nonenyl, 1-decenyl, 2-decenyl, 3-decenyl, 4-decenyl, 5-decenyl, 6-decenyl, 7-decenyl, 8-decenyl, 9-decenyl, 1-undecenyl, 2-undecenyl, 3-undecenyl, 4-undecenyl, 5-undecenyl, 6-undecenyl, 7-undecenyl, 8-undecenyl, 9-undecenyl, 10-undecenyl, I-dodecenyl, 2-dodecenyl, 3-dodecenyl, 4-dodecenyl, 5-dodecenyl, 6-dodecenyl, 7-dodecenyl, 8-dodecenyl, 9-dodecenyl, 10-dodecenyl, and 11-dodecenyl. Unless stated otherwise specifically in the specification, an alkyl group can be optionally substituted.

“haloalkoxy” refers to an alkoxy radical, as defined herein, that is substituted by one or more halo radicals, as defined above, e.g., —OCF₃, —OCHF₂, —OCH₂F, —OCF₂CF₃, or —OCH₂CF₃, and the like. Unless stated otherwise specifically in the specification, a haloalkyl group can be optionally substituted.

The term “substituted” used herein means any of the groups described herein (e.g., alkyl, haloalkyl, alkoxy and/or alkenyl) wherein at least one hydrogen atom is replaced by a bond to a non-hydrogen atoms such as, but not limited to: a halogen atom such as F, Cl, Br, and I; an oxygen atom in groups such as hydroxyl groups, alkoxy groups, and ester groups; a sulfur atom in groups such as thiol groups, thioalkyl groups, sulfone groups, sulfonyl groups, and sulfoxide groups; a nitrogen atom in groups such as amines, amides, alkylamines, dialkylamines, arylamines, alkylarylamines, diarylamines, N-oxides, imides, and enamines; a silicon atom in groups such as trialkylsilyl groups, dialkylarylsilyl groups, alkyldiarylsilyl groups, and triarylsilyl groups; and other heteroatoms in various other groups. For example, “substituted” includes any of the above groups in which one or more hydrogen atoms are replaced with —NR_(g)R_(h), —NR_(g)C(═O)R_(h), —NR_(g)C(═O)NR_(g)R_(h), —NR_(g)C(═O)OR_(h), —NR_(g)SO₂R_(h), —OC(═O)NR_(g)R_(h), —OR_(g), —SR_(g), —SOR_(g), —SO₂R_(g), —OSO₂R_(g), —SO₂OR_(g), ═NSO₂R_(g), and —SO₂NR_(g)R_(h). “Substituted” also means any of the above groups in which one or more hydrogen atoms are replaced with —C(═O)R_(g), —C(═O)OR_(g), —C(═O)NR_(g)R_(h), —CH₂SO₂R_(g), —CH₂SO₂NR_(g)R_(h). In the foregoing, R_(g) and R_(h) are the same or different and independently hydrogen, alkyl, alkenyl, alkynyl, alkoxy, alkylamino, thioalkyl, aryl, aralkyl, cycloalkyl, cycloalkenyl, cycloalkynyl, cycloalkylalkyl, haloalkyl, haloalkenyl, haloalkynyl, heterocyclyl, N-heterocyclyl, heterocyclylalkyl, heteroaryl, N-heteroaryl and/or heteroarylalkyl. “Substituted” further means any of the above groups in which one or more hydrogen atoms are replaced by a bond to an amino, cyano, hydroxyl, imino, nitro, oxo, thioxo, halo, alkyl, alkenyl, alkynyl, alkoxy, alkylamino, thioalkyl, aryl, aralkyl, cycloalkyl, cycloalkenyl, cycloalkynyl, cycloalkylalkyl, haloalkyl, haloalkenyl, haloalkynyl, heterocyclyl, N-heterocyclyl, heterocyclylalkyl, heteroaryl, N-heteroaryl and/or heteroarylalkyl group. In addition, each of the foregoing substituents can also be optionally substituted with one or more of the above substituents.

DETAILED DESCRIPTION

The present disclosure provides cannabinoid derivatives, such as cannabigerol (CBG), cannabidiol (CBD), derivatives for use in the treatment of various diseases or disorders.

There are a number of therapeutic conditions which may be treated effectively by cannabinoids including, for example, cancer pain, cancer, colorectal cancer, migraine, appetite stimulation, multiple sclerosis, spinal cord injury, peripheral neuropathy, other neurogenic pain, rheumatoid arthritis, inflammatory bowel diseases, psychotic disorders (schizophrenia), anxiety, epilepsy & movement disorders, neurodegenerative disorders, stroke, head injury, appetite suppression.

The activity of the endocannabinoid system (ECS) within the CNS is essential for normal mental health. CB₁ receptors are densely expressed in the cortex, hippocampus, amygdala, basal ganglia, and cerebellum. Of relevance to schizophrenia, CB₁ modulates release of dopamine and glutamate (as well as gamma-aminobutyric acid, serotonin, glycine, acetylcholine, and noradrenaline), and in participants their expression is increased in prefrontal cortex and anterior cingulate cortex. CB₁ knockout mice show increased emotional reactivity, hypersensitivity to stress, reduced responsiveness to rewarding stimuli, increased aggression to intruders, enhanced development of learned helplessness, impaired extinction of aversive memories, and social withdrawal (Robson et al, Current Pharmaceutical Design, 2014; 20(13): 2194-204).

An extensive review of the antipsychotic properties of CBD by Iseger et al. in 2015 (Schizophr. Res. March 2015; 162(1-3):153-61), which reviewed and referenced 29 studies incorporated by reference, concluded that CBD was an effective, safe and well tolerated antipsychotic compound, and thus may be a promising new agent in the treatment of schizophrenia. It has been postulated that CBD may have potential utility in schizophrenia, not only as an antipsychotic but also in the alleviation of the metabolic and inflammatory abnormalities associated with the disease. CBD has also demonstrated efficacy in anxiety. Unfortunately, CBD is not easily developable as an oral medication due to its poor bioavailability, which necessitates high oral doses leading to e.g., economic waste, risk of toxicity, and unpredictable responses. See for example, the clinical study described in McGuire et al. (Philip McGuire et al. Am J Psychiatry 2018; 175:225-231) where Schizophrenia patients were administered high doses of 1 gram of CBD.

Inflammatory bowel disease (IBD) comprises the chronic relapsing inflammatory disorders Crohn's disease (CD) and ulcerative colitis (UC). It is characterized by abdominal pain, diarrhoea, bleeding and malabsorption. Its incidence is increasing worldwide, and the disease remains incurable. The incidence and prevalence of IBD has increased in the past 50 years, up to 8-14/100,000 and 120-200/100,000 cases, respectively, for UC and 6-15/100,000 and 50-200/100,000 cases, respectively, for CD. Conventional therapies for IBD include antibodies treatments such as: ENTYVIO® (vedolizumab) and Stelara (ustekinumab), aminosalicylates, corticosteroids, thiopurines, methotrexate, and anti-tumor necrosis factor agents. Although these drugs may be effective, their long-term use can induce severe side effects that have detrimental impact on life quality of patients, and antibody treatments often require hospitalization and high treatment costs. Hence, new approaches with fewer side effects for the treatment of IBD are needed.

Studies have shown that Cannabis use is common in patients with IBD for symptom relief (Naftali T et al. Isr. Med. Assoc. J. 2011; 13:455-8; Lal S et al. Eur. J. Gastroenterol. Hepatol. 2011:23:891-6). A pilot prospective study found that treatment with inhaled Cannabis improved quality of life in patients with long-standing CD and UC (Lahat A et al. Digestion 2012; 85:1-8). In Israel, inhaled Cannabis has been legally registered for palliative treatment of both CD and UC. D9-tetrahydrocannabinol (D9-THC), the main Cannabis psychotropic ingredient which activates cannabinoid (CB1 and CB2) receptors, and cannabidiol (CBD), the best studied among the so-called non-psychotropic cannabinoids, have been previously shown to ameliorate experimental colitis in rodents (Borrelli F et al. J. Mol. Med. 2009:87:1111-21; Jamontt J M et al, Br. J. Pharmacol. 2010; 60:712-23; Schicho R et al. Pharmacology 2012; 89:149-55). A study by Borelli et al (Biochemical Pharmacology, 85 (2013) 1306-1316) demonstrated that cannabinoid CBG exerts protective effects in a murine experimental model of IBD.

In embodiments, the compounds of the present disclosure are designed to minimize glucuronidation. In embodiments, the compounds of the present disclosure are designed to minimize glucuronidation but do not convert to the parent compound e.g., cannabigerol (CBG), cannabidiol (CBD).

In embodiments, the cannabinoid derivatives of the present disclosure provide higher cannabinoid concentration in the plasma or target cells/organ such as the GI and colon and brain when compared to the parent cannabinoid. For example, CBG analogs of the present disclosure provide higher concentrations of the CBG analog in the plasma or target cells/organ such as the GI and colon when compared to CBG, or CBD analogs of the present disclosure provide higher CBD concentrations of the CBD analog in the plasma or target cells/organ such as the GI and colon when compared to CBD.

Compounds

In embodiments, provided herein is a compound of Formula (IV):

wherein:

R₁₀ is C₂₋₆alkyl, C₁₋₆alkyl-OH, or C₂₋₆alkenyl;

R^(E) is hydroxy, halo, —NR^(A)R^(B), cyano, nitro, alkyl, -haloalkyl, haloalkoxy or alkoxy;

R⁴, R^(4′), R⁵, R^(5′), R⁶, R^(6′), R⁷, R^(7′), R⁸, R^(8′), R⁹ are each independently selected from the group consisting of hydrogen, —OH, alkyl, alkoxy, —NR^(A)R^(B), and halogen;

R^(A) and R^(B) are each independently hydrogen or alkyl; and

n is 0, 1, or 2.

In embodiments, R₁₀ is —CH₂CH, —CH₂CH₂CH₃, —CH═CH₂, or —CH₂OH.

In embodiments, R⁴, R^(4′) are hydrogen. In embodiments, R⁵, R^(5′) are hydrogen. In embodiments, R⁶, R^(6′) are hydrogen. In embodiments, R⁷, R^(7′) are hydrogen. In embodiments, R⁸, and R^(8′).

In embodiments, R⁴, R^(4′), R⁵, R^(5′), R⁶, R^(6′), R⁷, R^(7′), R⁸, and R^(8′) are hydrogen.

In embodiments of the compounds of the present disclosure, R⁴, R^(4′), R⁵, R^(5′), R⁶, R^(6′), R⁷, R^(7′), R⁸, and R^(8′) are hydrogen and R⁹ is C₁₋₆ alkyl.

In embodiments of the compounds of the present disclosure, R⁴, R^(4′), R⁵, R^(5′), R⁶, R^(6′), R⁷, R^(7′), R⁸, and R^(8′) are hydrogen and R⁹ is —CH₂CH₃.

In embodiments, provided herein is a compound of Formula (V):

wherein:

R₁₀ is C₁₋₃ alkyl optionally substituted with —OH, or C₂₋₆alkenyl;

R³ is C₁₋₄ alkyl optionally substituted with —OH, or C₂₋₆alkenyl;

R^(E) is hydroxy, halo, —NR^(A)R^(B), cyano, nitro, alkyl, -haloalkyl, haloalkoxy or alkoxy;

R⁴, R^(4′), R⁵, R^(5′), R⁶, R^(6′), R⁷, R^(7′), R⁸, R^(8′), R⁹ are each independently selected from the group consisting of hydrogen, —OH, alkyl, alkoxy, —NR^(A)R^(B), and halogen;

R^(A) and R^(B) are each independently hydrogen or alkyl; and

n is 0, 1, or 2.

In embodiments of the compounds of the present disclosure, R⁴, R^(4′) R⁵, R^(5′), R⁶, R^(6′), R⁷, R^(7′), R⁸, and R^(8′) are hydrogen.

In embodiments, R⁴, R^(4′) are hydrogen. In embodiments, R⁵, R^(5′) are hydrogen. In embodiments, R⁶, R^(6′) are hydrogen. In embodiments, R⁷, R^(7′) are hydrogen. In embodiments, R⁸, and R^(8′).

In embodiments of the compounds of the present disclosure, R⁴, R^(4′), R⁵, R^(5′), R⁶, R^(6′), R⁷, R^(7′), R⁸, and R^(8′) are hydrogen and R⁹ is C₁₋₆ alkyl.

In embodiments of the compounds of the present disclosure, R⁴, R^(4′), R⁵, R^(5′), R⁶, R^(6′), R⁷, R^(7′), R⁸, and R^(8′) are hydrogen and R⁹ is —CH₂CH₃.

In embodiments, R₁₀ is CH₃, R₁₀ is —CH₂CH₃, —CH₂CH₂CH₃, —CH═CH₂, or —CH₂OH.

In embodiments, R³ is —CH₂CH₃, —CH₂CH₂CH₃, —CH₂CH₂CH₂CH₃, —CH₂—CH═CH₂, or —CH₂CH₂—OH.

In embodiments, provided herein is one or more compounds selected from Table 1.

In embodiments, provided herein is one or more pharmaceutically acceptable salts of a compound selected from Table 1.

TABLE 1 Compounds No. Structure  5

 6

 7

 8

 9

10

11

12

13

15

16

18

19

Compositions

In some embodiments of the present disclosure, a pharmaceutical composition comprises a therapeutically effective amounts of one or more compounds of the present disclosure (e.g., a compound of Formula (I), (I), (III), (IV), or (V), Table 1 or Table 2) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

In some embodiments of the present disclosure, a pharmaceutical composition comprises a therapeutically effective amounts of a compound of Formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

wherein:

-   -   R¹ and R³ are independently a hydrogen, optionally substituted         alkyl, or alkenyl;     -   R² is

-   -   R^(E) is hydroxy, halo, —NR^(A)R^(B), cyano, nitro, alkyl,         -haloalkyl, haloalkoxy or alkoxy;     -   R⁴, R^(4′), R⁵, R^(5′), R⁶, R^(6′), R⁷, R^(7′), R⁸, R^(8′), R⁹         are each independently selected from the group consisting of         hydrogen, —OH, alkyl, alkoxy, —NR^(A)R^(B), and halogen;     -   R^(A) and R^(B) are each independently hydrogen or alkyl; and     -   n is 0, 1, or 2.

In some embodiments, a pharmaceutical composition, as described herein, comprises one or more compounds selected from Table 1, or a pharmaceutically acceptable salt thereof or stereoisomer thereof.

In some embodiments, a pharmaceutical composition, as described herein, comprises one or more compounds selected from Table 1, or a pharmaceutically acceptable salt thereof.

In some embodiments of the present disclosure, a pharmaceutical composition comprising one or more compounds of the present disclosure or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient or adjuvant is provided. The pharmaceutically acceptable excipients and adjuvants are added to the composition or formulation for a variety of purposes. In some embodiments, a pharmaceutical composition comprising one or more compounds disclosed herein, or a pharmaceutically acceptable salt thereof, further comprise a pharmaceutically acceptable carrier. In some embodiments, a pharmaceutically acceptable carrier includes a pharmaceutically acceptable excipient, binder, and/or diluent. In some embodiments, suitable pharmaceutically acceptable carriers include, but are not limited to, inert solid fillers or diluents and sterile aqueous or organic solutions. In some embodiments, suitable pharmaceutically acceptable excipients include, but are not limited to, water, salt solutions, alcohol, polyethylene glycols, gelatin, lactose, amylase, magnesium stearate, talc, silicic acid, viscous paraffin, and the like.

For the purposes of this disclosure, the compounds of the present disclosure can be formulated for administration by a variety of means including orally, parenterally, by inhalation spray, topically, or rectally in formulations containing pharmaceutically acceptable carriers, adjuvants and vehicles. The term parenteral as used here includes subcutaneous, intravenous, intramuscular, and intraarterial injections with a variety of infusion techniques. Intraarterial and intravenous injection as used herein includes administration through catheters.

Generally, the compounds of the present disclosure are administered in a therapeutically effective amount. The amount of the compound actually administered will typically be determined by a physician, in the light of the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound-administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the like.

Therapeutic Use

In embodiments, the present disclosure provides a method of treating a chronic inflammatory disease, cancer, or a mental health disorder in a subject in need thereof, comprising administering a compound of Formula (I), or a pharmaceutically acceptable salt thereof

wherein:

-   -   R¹ and R³ are independently a hydrogen, optionally substituted         alkyl, or alkenyl;     -   R² is

-   -   R^(E) is hydroxy, halo, —NR^(A)R^(B), cyano, nitro, alkyl,         -haloalkyl, haloalkoxy or alkoxy;     -   R⁴, R^(4′), R⁵, R^(5′), R⁶, R^(6′), R⁷, R^(7′), R⁸, R^(8′) are         each independently selected from the group consisting of         hydrogen, —OH, alkyl, alkoxy, —NR^(A)R^(B), and halogen;     -   R^(A) and R^(B) are each independently hydrogen or alkyl; and     -   n is 0, 1, or 2.

In embodiments, the present disclosure provides a method of treating a chronic inflammatory disease, cancer, or a mental health disorder in a subject in need thereof, comprising administering a compound of Formula (I), or a pharmaceutically acceptable salt thereof

wherein:

-   -   R¹ and R³ are independently a hydrogen, optionally substituted         alkyl or alkenyl;     -   R² is

-   -   R^(E) is hydroxy, halo, —NR^(A)R^(B), cyano, nitro, alkyl,         -haloalkyl, haloalkoxy or alkoxy;     -   R⁴, R^(4′), R⁵, R^(5′), R⁶, R^(6′), R⁷, R^(7′), R⁸, and R^(8′)         are each independently selected from the group consisting of         hydrogen, —OH, alkyl, alkoxy, —NR^(A)R^(B), and halogen; and     -   R⁹ is alkyl;     -   R^(A) and R^(B) are each independently hydrogen or alkyl; and     -   n is 0, 1, or 2.

In embodiments of the methods of the present disclosure, the compound of Formula (I) is

-   -   or a pharmaceutically acceptable salt thereof

wherein:

-   -   R¹ and R³ are independently a hydrogen, optionally substituted         alkyl or alkenyl;     -   R² is

-   -   R^(E) is hydroxy, halo, —NR^(A)R^(B), cyano, nitro, alkyl,         -haloalkyl, haloalkoxy or alkoxy; and     -   n is 0, 1, or 2.

In embodiments, the present disclosure provides a method of treating a chronic inflammatory disease, cancer, or a mental health disorder in a subject in need thereof, comprising administering a compound of Formula (I), or a pharmaceutically acceptable salt thereof

wherein:

-   -   R¹ and R³ are independently a hydrogen, alkyl, alkyl-OH, or         alkenyl; provided that at least one of R¹ and R³ is not         hydrogen;     -   R² is

-   -   R^(E) is hydroxy, halo, —NR^(A)R^(B), cyano, nitro, alkyl,         -haloalkyl, haloalkoxy or alkoxy;     -   R⁴, R^(4′), R⁵, R^(5′), R⁶, R^(6′), R⁷, R^(7′), R⁸, R^(8′), R⁹         are each independently selected from the group consisting of         hydrogen, —OH, alkyl, alkoxy, —NR^(A)R^(B), and halogen;     -   R^(A) and R^(B) are each independently hydrogen or alkyl; and     -   n is 0, 1, or 2.

In embodiments, the present disclosure provides a method of treating a chronic inflammatory disease, cancer, or a mental health disorder in a subject in need thereof, comprising administering a compound of Formula (I), or a pharmaceutically acceptable salt thereof

wherein:

-   -   R¹ and R³ are independently a hydrogen or alkyl; provided that         at least one of R¹ and R³ is alkyl;     -   R² is

-   -   R^(E) is hydroxy, halo, —NR^(A)R^(B), cyano, nitro, alkyl,         -haloalkyl, haloalkoxy or alkoxy;     -   R⁴, R^(4′), R⁵, R^(5′), R⁶, R^(6′), R⁷, R^(7′), R⁸, R^(8′), R⁹         are each independently selected from the group consisting of         hydrogen, —OH, alkyl, alkoxy, —NR^(A)R^(B), and halogen;     -   R^(A) and R^(B) are each independently hydrogen or -alkyl; and     -   n is 0, 1, or 2.

In embodiments, the present disclosure provides a method of treating a chronic inflammatory disease or mental health disorder in a subject in need thereof, comprising administering a compound of Formula (I), or a pharmaceutically acceptable salt thereof

wherein:

-   -   R¹ and R³ are independently a hydrogen or alkyl; provided that         at least one of R¹ and R³ is alkyl;     -   R² is

-   -   R^(E) is hydroxy, halo, —NR^(A)R^(B), cyano, nitro, alkyl,         -haloalkyl, haloalkoxy or alkoxy;     -   R⁴, R^(4′), R⁵, R^(5′), R⁶, R^(6′), R⁷, R^(7′), R⁸, R^(8′), R⁹         are each independently selected from the group consisting of         hydrogen, —OH, alkyl, alkoxy, —NR^(A)R^(B), and halogen;     -   R^(A) and R^(B) are each independently hydrogen or -alkyl; and     -   n is 0, 1, or 2.

In embodiments of the compounds of Formula (I), R¹ and R³ are each independently a hydrogen, alkyl optionally substituted with OH, or alkenyl.

In embodiments of the compounds of Formula (I), R¹ is hydrogen and R³ is alkyl.

In embodiments of the compounds of Formula (I), R¹ is hydrogen and R³ is —C₁₋₆alkyl.

In embodiments of the compounds of Formula (I), R¹ is hydrogen and R³ is —C₂₋₆alkyl.

In embodiments of the compounds of Formula (I), R¹ is hydrogen and R³ is —C₁₋₃alkyl.

In embodiments of the compounds of Formula (I), R¹ is hydrogen and R³ is one or more substituents (e.g., 1, 2, 3, 4 5, or 6 substituents) selected from the group consisting of methyl, ethyl, propyl, butyl, —CH₂—CH═CH₂, and —CH₂CH₂—OH. In embodiments, R¹ is hydrogen and R³ is methyl, ethyl, propyl, butyl, —CH₂—CH═CH₂, or —CH₂CH₂—OH.

In embodiments of the compounds of Formula (I), R¹ is hydrogen and R³ is methyl.

In embodiments of the compounds of Formula (I), R¹ and R³ are alkyl.

In embodiments of the compounds of Formula (I), R¹ and R³ are independently —C₁₋₆alkyl.

In embodiments of the compounds of Formula (I), R¹ and R³ are independently —C₁₋₃alkyl.

In embodiments of the compounds of Formula (I), R¹ and R³ are each independently one or more substituents (e.g., 1, 2, 3, 4 5, or 6 substituents) selected from the group consisting of methyl, ethyl, propyl, butyl, —CH₂—CH═CH₂, and —CH₂CH₂—OH. In embodiments, R¹ and R³ are each independently methyl, ethyl, propyl, butyl, —CH₂—CH═CH₂, or —CH₂CH₂—OH.

In embodiments of the compounds of Formula (I), R¹ and R³ are methyl.

In embodiments of the compounds of Formula (I), R² is

In embodiments of the compounds of Formula (I),

-   -   R² is

In embodiments of the compounds of Formula (I),

-   -   R² is

In embodiments of the compounds of Formula (I), R⁴, R^(4′), R⁵, R^(5′), R⁶, R^(6′), R⁷, R^(7′), R⁸, R^(8′), R⁹ are each independently selected from the group consisting of hydrogen, —OH, alkyl, alkoxy, —NR^(A)R^(B), and halogen.

In embodiments of the compounds of Formula (I), R⁴, R^(4′), R⁵, R^(5′), R⁶, R^(6′), R⁷, R^(7′), R⁸, R^(8′), R⁹ are each hydrogen.

In embodiments of the compounds of Formula (I), R⁴, R^(4′), R⁵, R^(5′), R⁶, R^(6′), R⁷, R^(7′), R⁸, and R^(8′) are each hydrogen R⁹ is —CH₂CH₃.

In embodiments of the compounds of Formula (I), R^(A) and R^(B) are each independently hydrogen or -alkyl.

In embodiments of the compounds of Formula (I), R^(A) and R^(B) are hydrogen. In embodiments, R^(A) and R^(B) are -alkyl.

In embodiments of the compounds of Formula (I), n is 0, 1, or 2. In embodiments, n is 0. In embodiments, n is 1. In embodiments, n is 2.

In embodiments of the methods of the present disclosure, the compound of Formula (I) is a compound of Formula (II):

wherein

R¹ and R³ are independently a hydrogen, alkyl, alkyl-OH, or alkenyl; provided that at least one of R¹ and R³ is not hydrogen;

R^(E) is hydroxy, halo, —NR^(A)R^(B), cyano, nitro, alkyl, -haloalkyl, haloalkoxy or alkoxy;

R⁴, R^(4′), R⁵, R^(5′), R⁶, R^(6′), R⁷, R^(7′), R⁸, R^(8′), R⁹ are each independently selected from the group consisting of hydrogen, —OH, alkyl, alkoxy, —NR^(A)R^(B), and halogen;

R^(A) and R^(B) are each independently hydrogen or alkyl; and

n is 0, 1, or 2.

In embodiments of the compounds of Formula (II), R¹ is hydrogen and R³ is alkyl.

In embodiments of the compounds of Formula (II), R¹ is hydrogen and R³ is —C₁₋₆alkyl.

In embodiments of the compounds of Formula (II), R¹ is hydrogen and R³ is methyl, ethyl, propyl, butyl, —CH₂—CH═CH₂, —CH₂CH₂—OH.

In embodiments of the compounds of Formula (II), R¹ and R³ are alkyl.

In embodiments of the compounds of Formula (U), R¹ and R³ are each independently —C₁₋₆alkyl.

In embodiments of the compounds of Formula (H), R¹ and R³ are each independently methyl, ethyl, propyl, butyl, —CH₂—CH═CH₂, or —CH₂CH₂—OH.

In embodiments of the compounds of Formula (II), R⁴, R^(4′), R⁵, R^(5′), R⁶, R^(6′), R⁷, R^(7′), R⁸, R^(8′), R⁹ are each hydrogen.

In embodiments of the compounds of Formula (II), R⁴, R^(4′), R⁵, R^(5′), R⁶, R^(6′), R⁷, R^(7′), R⁸, and R^(8′) are each hydrogen R⁹ is —CH₂CH₃.

In embodiments of the compounds of Formula (II), n is 0, 1, or 2. In embodiments, n is 0. In embodiments, n is 1. In embodiments, n is 2.

In embodiments of the methods of the present disclosure, the compound of Formula (I) is a compound of Formula (III):

wherein

R¹ and R³ are independently a hydrogen, alkyl, alkyl-OH, or alkenyl; provided that at least one of R¹ and R³ is not hydrogen;

R^(E) is hydroxy, halo, —NR^(A)R^(B), cyano, nitro, alkyl, -haloalkyl, haloalkoxy or alkoxy;

R⁴, R^(4′), R⁵, R^(5′), R⁶, R^(6′), R⁷, R^(7′), R⁸, R^(8′), R⁹ are each independently selected from the group consisting of hydrogen, —OH, alkyl, alkoxy, —NR^(A)R^(B), and halogen;

R^(A) and R^(B) are each independently hydrogen or alkyl; and

n is 0, 1, or 2.

In embodiments of the compounds of Formula (III), R¹ is hydrogen and R³ is alkyl.

In embodiments of the compounds of Formula (III), R¹ is hydrogen and R³ is —C₁₋₆alkyl.

In embodiments of the compounds of Formula (III), R¹ is hydrogen and R³ is methyl.

In embodiments of the compounds of Formula (III), R¹ and R³ are alkyl.

In embodiments of the compounds of Formula (III), R¹ and R³ are independently —C₁₋₆alkyl.

In embodiments of the compounds of Formula (III), R¹ and R³ are each independently methyl.

In embodiments of the compounds of Formula (III), R⁴, R^(4′), R⁵, R^(5′), R⁶, R^(6′), R⁷, R^(7′), R⁸, R^(8′), R⁹ are each hydrogen.

In embodiments of the compounds of Formula (III), R⁴, R^(4′), R⁵, R^(5′), R⁶, R^(6′), R⁷, R^(7′), R⁸, and R^(8′) are each hydrogen and R⁹ is —CH₂CH₃.

In embodiments of the compounds of Formula (III), n is 0, 1, or 2. In embodiments, n is 0. In embodiments, n is 1. In embodiments, n is 2.

In embodiments of the methods of the present disclosure, the methods comprise administering a compound of Formula (IV):

-   -   or a pharmaceutically acceptable salt thereof

wherein:

R₁₀ is C₂₋₆alkyl, C₁₋₆alkyl-OH, or C₂₋₆alkenyl;

R^(E) is hydroxy, halo, —NR^(A)R^(B), cyano, nitro, alkyl, -haloalkyl, haloalkoxy or alkoxy;

R⁴, R^(4′), R⁵, R^(5′), R⁶, R^(6′), R⁷, R^(7′), R⁸, R^(8′), R⁹ are each independently selected from the group consisting of hydrogen, —OH, alkyl, alkoxy, —NR^(A)R^(B), and halogen;

R^(A) and R^(B) are each independently hydrogen or alkyl; and

n is 0, 1, or 2.

In embodiments, R₁₀ is —CH₂CH₃, —CH₂CH₂CH₃, —CH═CH₂, or —CH₂OH.

In embodiments, R⁴, R^(4′) are hydrogen. In embodiments, R⁵, R^(5′) are hydrogen. In embodiments, R⁶, R^(6′) are hydrogen. In embodiments, R⁷, R^(7′) are hydrogen. In embodiments, R⁸, and R^(8′).

In embodiments, R⁴, R^(4′), R⁵, R^(5′), R⁶, R^(6′), R⁷, R^(7′), R⁸, and R^(8′) are hydrogen.

In embodiments of the compounds of the present disclosure, R⁴, R^(4′), R⁵, R^(5′), R⁶, R^(6′), R⁷, R^(7′), R⁸, and R^(8′) are hydrogen and R⁹ is C₁₋₆ alkyl.

In embodiments of the compounds of the present disclosure, R⁴, R^(4′), R⁵, R^(5′), R⁶, R^(6′), R⁷, R^(7′), R⁸, and R^(8′) are hydrogen and R⁹ is —CH₂CH₃.

In embodiments of the methods of the present disclosure, the methods comprise administer in a compound of Formula (V):

-   -   or a pharmaceutically acceptable salt thereof

wherein:

R₁₀ is C₁₋₃ alkyl optionally substituted with —OH, or C₂₋₆alkenyl;

R₃ is C₁₋₄ alkyl optionally substituted with —OH, or C₂₋₆alkenyl;

R^(E) is hydroxy, halo, —NR^(A)R^(B), cyano, nitro, alkyl, -haloalkyl, haloalkoxy or alkoxy;

R⁴, R^(4′), R⁵, R^(5′), R⁶, R^(6′), R⁷, R^(7′), R⁸, R^(8′), R⁹ are each independently selected from the group consisting of hydrogen, —OH, alkyl, alkoxy, —NR^(A)R^(B), and halogen;

R^(A) and R^(B) are each independently hydrogen or alkyl; and

n is 0, 1, or 2.

In embodiments of the compounds of the present disclosure, R⁴, R^(4′), R⁵, R^(5′), R⁶, R^(6′), R⁷, R^(7′), R⁸, and R^(8′) are hydrogen.

In embodiments, R⁴, R^(4′) are hydrogen. In embodiments, R⁵, R^(5′) are hydrogen. In embodiments, R⁶, R^(6′) are hydrogen. In embodiments, R⁷, R^(7′) are hydrogen. In embodiments, R⁸, and R^(8′).

In embodiments, R⁴, R^(4′), R⁵, R^(5′), R⁶, R^(6′), R⁷, R^(7′), R⁸, and R^(8′) are hydrogen and R⁹ is C₁₋₆ alkyl.

In embodiments e, R⁴, R^(4′), R⁵, R^(5′), R⁶, R^(6′), R⁷, R^(7′), R⁸, and R^(8′) are hydrogen and R⁹ is —CH₂CH₃.

In embodiments, R₁₀ is CH₃, R₁₀ is —CH₂CH₃, —CH₂CH₂CH₃, —CH═CH₂, or —CH₂OH.

In embodiments, R³ is —CH₂CH₃, —CH₂CH₂CH₃, —CH₂CH₂CH₂CH₃, —CH₂—CH═CH₂, or —CH₂CH₂—OH.

In embodiments of the methods of the present disclosure, one or more compounds selected from Table 1 or 2 is administered to a subject in need thereof.

In embodiments of the methods of the present disclosure, one or more pharmaceutically acceptable salts of a compound selected from Table 1 or 2 is administered to a subject in need thereof.

TABLE 2 Compounds No. Structure  1

 2

 3

 4

 5

 6

 7

 8

 9

10

11

12

13

14

15

16

17

18

19

In embodiments of the methods disclosed herein the compound is

In embodiments of the methods disclosed herein, the compound is

In embodiments, the compound is

In embodiments of the methods of the present disclosure, the method comprises administering as an active agent a compound of the present disclosure (e.g., a compound of Formula (I), (II), (III), (IV), (V), Table 1 or Table 2) or a pharmaceutically acceptable salt thereof.

In embodiments of the methods of the present disclosure, the method comprises administering an effective amount of a compound consisting of a compound of the present disclosure (e.g., a compound of Formula (I), (II), (III), (IV), (V), Table 1 or Table 2) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient or carrier. In embodiments of the methods of the present disclosure, the method comprises administering a composition consisting of a compound of the present disclosure (e.g., a compound of Formula (I), (II), (III), Table 1 or Table 2) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient or carrier.

In embodiments of the methods of the present disclosure, the method comprises administering as an active agent a cannabinoid selected from a compound of the present disclosure (e.g., a compound of Formula (I), (II), (III), (IV), (V), Table 1 or Table 2) or a pharmaceutically acceptable salt thereof.

In embodiments, the present disclosure provides a method of treating a chronic inflammatory disease in a subject in need thereof, comprising administering a compound of the present disclosure (e.g., a compound of Formula (I), (II), (III), (IV), (V), Table 1, or Table 2) or a pharmaceutically acceptable salt thereof.

In embodiments, the present disclosure provides a method of treating pain in a subject in need thereof, comprising administering a compound of the present disclosure (e.g., a compound of Formula (I), (II), (III), (IV), (V), Table 1, or Table 2), or a pharmaceutically acceptable salt thereof.

In embodiments, the present disclosure provides a method of treating colon cancer in a subject in need thereof, comprising administering a compound of the present disclosure (e.g., a compound of Formula (I), (II), (III), (IV), (V), Table 1, or Table 2), or a pharmaceutically acceptable salt thereof.

In embodiments, the present disclosure provides a method of treating a mental health disorder in a subject in need thereof, comprising administering a compound of the present disclosure (e.g., a compound of Formula (I), (II), (III), (IV), (V), Table 1, or Table 2), or a pharmaceutically acceptable salt thereof.

In embodiments, the present disclosure provides a method of treating neurodegeneration in a subject in need thereof, comprising administering a compound of the present disclosure (e.g., a compound of Formula (I), (II), (III), (IV), (V), Table 1, or Table 2), or a pharmaceutically acceptable salt thereof. In some embodiments, methods of treating neurodegeneration in a subject with amyotrophic lateral sclerosis (ALS) is provided.

In embodiments, the mental health disorder is anxiety.

In embodiments, the mental health disorder is schizophrenia.

In embodiments, the present disclosure provides a method of treating epilepsy in a subject in need thereof, comprising administering a compound of the present disclosure (e.g., a compound of Formula (I), (II), (III), Table 1, (IV), (V), or Table 2), or a pharmaceutically acceptable salt thereof. Types of epilepsy can include, but are not limited to Angelman Syndrome, Lennox Gaustaux, Dravet, Tuberous sclerosis, Landau Kleffner, Otahara, or West's disease.

In embodiments, the present disclosure provides a method of treating seizure (e.g., seizures as disclosed herein) in a subject in need thereof, comprising administering a compound of the present disclosure (e.g., a compound of Formula (I), (II), (III), (IV), (V), Table 1, or Table 2), or a pharmaceutically acceptable salt thereof. Seizures as described herein can include epileptic seizures (e.g., as disclosed herein).

In embodiments, the compounds of the present disclosure are used for treating a chronic inflammatory disease in a subject in need thereof, comprising administering a compound of the present disclosure (e.g., a compound of Formula (I), (II), (III), (IV), (V), Table 1, or Table 2), or a pharmaceutical composition comprising a compound of the present disclosure (e.g., a compound of Formula (I), (II), (III), (IV), (V), Table 1, or Table 2).

In embodiments, the disease is an inflammatory bowel disease (IBD).

In embodiments, the inflammatory bowel disease is Crohn's disease.

In embodiments, the inflammatory bowel disease is ulcerative colitis.

In embodiments of any one of the methods described herein, the subject is human.

Compounds of the present disclosure can be formulated as a pharmaceutical composition. In embodiments, such a pharmaceutical composition comprises a compound of the present disclosure (e.g., a compound of Formula (I), (II), (III), (IV), (V), Table 1, or Table 2)) or a pharmaceutically acceptable salt thereof. In embodiments, the composition further comprises a pharmaceutically acceptable carrier.

In embodiments of the present disclosure, a pharmaceutical composition comprising one or more compounds of the present disclosure (e.g., a compound of Formula (I), (II), (III), (IV), (V), Table 1, or Table 2) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient or adjuvant is provided. The pharmaceutically acceptable excipients and adjuvants are added to the composition or formulation for a variety of purposes. In embodiments, a pharmaceutical composition comprising one or more compounds disclosed herein, or a pharmaceutically acceptable salt thereof, further comprise a pharmaceutically acceptable carrier. In embodiments, a pharmaceutically acceptable carrier includes a pharmaceutically acceptable excipient, binder, and/or diluent. In embodiments, suitable pharmaceutically acceptable carriers include, but are not limited to, inert solid fillers or diluents and sterile aqueous or organic solutions. In embodiments, suitable pharmaceutically acceptable excipients include, but are not limited to, water, salt solutions, alcohol, polyethylene glycols, gelatin, lactose, amylase, magnesium stearate, talc, silicic acid, viscous paraffin, and the like.

In embodiments, the compositions of the present disclosure can provide therapeutic concentrations of a compound of the present disclosure (e.g., a compound of Formula (I), (II), (III), (IV), (V), Table 1, or Table 2) upon administration to a subject.

For the purposes of this disclosure, the compounds of the present disclosure can be formulated for administration by a variety of means including orally, parenterally, by inhalation spray, topically, or rectally in formulations containing pharmaceutically acceptable carriers, adjuvants and vehicles. The term parenteral as used here includes subcutaneous, intravenous, intramuscular, and intraarterial injections with a variety of infusion techniques. In embodiments, the compounds of the present disclosure can be formulated for intraperitoneal administration. Intraarterial and intravenous injection as used herein includes administration through catheters.

Generally, the compounds of the present disclosure are administered in a therapeutically effective amount. The amount of the compound actually administered will typically be determined by a physician, in the light of the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound-administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the like.

EXAMPLES

The disclosure now being generally described, it will be more readily understood by reference to the following examples which are included merely for purposes of illustration of certain aspects and embodiments of the present disclosure and are not intended to limit the invention.

The compounds of the present disclosure can be synthesized using the methods as hereinafter described below, together with synthetic methods known in the art of synthetic organic chemistry or variations thereon as appreciated by those skilled in the art.

Example 1: Synthesis of (E)-2-(3,7-dimethylocta-2,6-dien-1-yl)-3-methoxy-5-pentylphenol (1) and (E)-2-(3,7-dimethylocta-2,6-dien-1-yl)-1,3-dimethoxy-5-pentylbenzene (2)

A 100 mL single neck round bottom flask was charged with cannabigerol (6.32 g; 20 mmol), DMF (50 mL), K₂CO₃ (5.0 g; 36.18 mmol) and were stirred at room temperature for 15 minutes. To this solution methyl iodide (2.84 g; 20 mmol) was added, the reaction mixture was stirred at room temperature for 18 hours. The reaction was monitored by LCMS and TLC (5% ethyl acetate in hexanes). LCMS shows 29% of cannabigerol, 38% of Compound 1, 32% of Compound 2. The reaction mixture was diluted with water (150 mL) and extracted with Ethyl acetate (2×100 mL). Combined organic layer was washed with brine. The organic layer was dried over Na₂SO₄ and evaporated solvent. The crude residue was chromatographed (ISCO system). Elution with 0-1% Ethyl acetate in Hexane, isolated Compound 2 (1.0 g, 14.54% yield) as colorless oil and purity >98% by LCMS and NMR. Further elution with 1-5% Ethyl acetate in Hexane, pure fractions were concentrated to obtain Compound 1 (1.5 g, 22.83% yield) as red oil and purity >98% by LCMS and NMR. Both compounds were characterized by ¹H,¹³C NMR (CDCl₃), and analyzed by LCMS.

Compound 1: ESI LCMS [M+H]⁺ C₂₂H₃₄O₂ calculated 331.26, found 331.90. FIG. 1 shows a ¹H NMR (CDCl₃) spectrum of Compound 1. FIG. 2 shows a ¹³C NMR (CDCl₃) spectrum of Compound 1. ¹H NMR and ¹³C NMR spectra were obtained 25° C. on a Merc200-mercury300 spectrometer.

Compound 2: ESI LCMS [M+H]⁺ C₂₃H₃₆O₂ calculated 345.27 found 345.65 and 221.57. FIG. 3 shows a ¹H NMR (CDCl₃) spectrum of Compound 2. FIG. 4 shows a ¹³C NMR (CDCl₃) spectrum of Compound 2. ¹H NMR and ¹³C NMR spectra were obtained 25° C. on a Merc200-mercury300 spectrometer.

Example 2: Quantification CBG and CBG Glucuronide in Rat Plasma and Brain

The purpose of this study was to quantify cannabigerol (CBG) in rat plasma and brain.

Protocol

Seven- to nine-week-old male and female Sprague-Dawley received either a single dose or once daily dosing for 21 days of vehicle or CBG at three different dosage levels as shown in the Table below.

Test Dosages Male Female Group Article (mg/kg b.w.) Route Frequency Rat Rat 1. Vehicle 0 Oral Once 3 3 Gavage daily 2. CBG 10 Oral Once 3 3 Gavage 3. CBG 30 Oral Once 3 3 Gavage 4. CBG 100 Oral Once 3 3 Gavage 5. CBG 10 Oral Once 3 3 Gavage daily 6. CBG 30 Oral Once 3 3 Gavage daily 7 CBG 100 Oral Once 3 3 Gavage daily

Approximately 0.2-0.25 mL blood was collected during the first 24 hours after the single dose, and at multiple times points after the terminal dose for the animals receiving daily dosing for 21 days. Liver, kidney, and colon samples were collected and fixed in 10% NBF for 48 hours, then stored in 70% ethanol at room temperature. Brain samples were collected and flash frozen.

LC-MS Analysis

Analytical curves were constructed using non-zero standards with CBG concentration ranging from 0.0025 to 2.500 μg/mL and 2.500-100.0 μg/mL in blank rat plasma samples and 1.0 to 2500 ng/mL in blank brain tissues. A blank sample was used to exclude contamination. The linearity of the relationship between peak area ratio and concentration was demonstrated by the correlation coefficients (r=0.9970).

LC-MS/MS Conditions:

Instrument Used: AB SCIEX QTRAP 4500/Shimadzu Prominence LC

Gradient Program Chromatographic Conditions Time % A % B Column: Waters C18, 2.1 × 50 mm, 0.01 95 5 3.5 μm Mobile Phase A: 0.1% Formic acid in 0.50 95 5 purified deionized H₂O Mobile Phase B: 0.1% Formic acid in 1.00 5 95 acetonitrile Flow Rate: 0.4 mL/min 3.50 5 95 Injection 10 μL 3.60 95 5 Volume: Run Time: 5.6 min 5.60 5 5

Results

The CBG and CBG glucuronide concentration in rat plasma on Day's 1 and 21 of the study is shown in Tables 1-4 below.

The concentration of CBG in plasma was shown to be low or below the level of quantitation (BLQ) (see Table 1-A and Table 2-A) and was not detected in brain (See Table 3).

CBG demonstrated very high first pass metabolism to the glucuronide upon oral administration (See Table 4 and Table 5).

TABLE 1-A CBG concentration in rat plasma (Day 1). CBG concentration (ng/mL) 15 Min 30 Min I hr 2 hr 4 hr 8 hr 24 hr Rat ID post Rx post Rx post Rx post Rx post Rx post Rx post Rx Group 2 16013777 M BLQ BLQ BLQ 11.5 BLQ BLQ BLQ CBG 16013786 M BLQ BLQ BLQ BLQ BLQ BLQ BLQ 10 mg/kg 16013790 M BLQ BLQ  7.3 12.0 BLQ BLQ BLQ 16013909 F BLQ BLQ  5.3 10.7 BLQ BLQ BLQ 16013914 F BLQ BLQ BLQ BLQ BLQ BLQ BLQ 16013918 F BLQ BLQ 18.6 14.6 BLQ BLQ BLQ Group 3 16013784 M 3.8 15.2 22.9 BLQ 24.5 BLQ BLQ CBG 16013789 M 7.6 BLQ 32.3 11.0 BLQ BLQ BLQ 30 mg/kg 16013791 M BLQ BLQ 32.5 BLQ BLQ BLQ BLQ 16013904 F BLQ BLQ  1.08 26.6 54.3 BLQ BLQ 16013912 F BLQ BLQ 31.2 78.6 62.1 BLQ BLQ 16013915 F BLQ BLQ 35.9 36.0 48.3 BLQ 2.75 Group 4 16013782 M BLQ BLQ BLQ BLQ BLQ BLQ BLQ CBG 16013793 M BLQ BLQ BLQ BLQ BLQ BLQ BLQ 100 mg/kg 16013794 M BLQ BLQ BLQ BLQ 119.0  BLQ BLQ 16013907 F BLQ BLQ BLQ BLQ BLQ BLQ BLQ 16013908 F BLQ BLQ BLQ BLQ BLQ BLQ BLQ 16013913 F BLQ BLQ BLQ BLQ 143.0  BLQ BLQ BLQ—Below Limit of Quantification (2.5 ng/mL)

TABLE 2-A CBG concentration in rat plasma (Day 21). Concentration (ng/mL) 15 min 30 min I hr 2 hr 4 hr 8 hr 24 hr Dose Rat ID post Rx post Rx post Rx post Rx post Rx post Rx post Rx Group 1 16013783 M BLQ Vehicle 16013792 M 16013795 M 16013902 F 16013911 F 16013917 F Group 5 16013780 M BLQ BLQ BLQ BLQ BLQ BLQ BLQ CBG 16013785 M BLQ BLQ   1.67  5.6   4.73 BLQ BLQ 10 mg/kg 16013796 M BLQ BLQ BLQ BLQ BLQ BLQ BLQ 16013903 F BLQ BLQ BLQ  9.5 BLQ 2.55 BLQ 16013916 F BLQ BLQ   2.75   2.72   8.49 BLQ BLQ 16013919 F BLQ BLQ BLQ BLQ BLQ 4.18 BLQ Group 6 16013776 M BLQ BLQ BLQ BLQ BLQ BLQ BLQ CBG 16013778 M BLQ BLQ BLQ BLQ BLQ BLQ BLQ 30 mg/kg 16013779 M 14.7 BLQ BLQ BLQ BLQ BLQ BLQ 16013799 F BLQ BLQ BLQ BLQ BLQ BLQ BLQ 16013901 F  4.51 BLQ BLQ BLQ BLQ BLQ BLQ 16013906 F  9.12 BLQ BLQ BLQ BLQ BLQ BLQ Group 7 16013781 M BLQ BLQ BLQ 307.0 BLQ BLQ BLQ CBG 16013787 M BLQ BLQ BLQ 201.0 171.0 BLQ BLQ 100 mg/kg 16013788 M BLQ BLQ BLQ 278.0 129.5 215.0 BLQ 16013798 F BLQ 178.5 225.5 BLQ 185.0 905.0 BLQ 16013900 F BLQ 122.5 206.0 275.5 905.0 3095.0 BLQ 16013910 F 41.6 BLQ BLQ BLQ 417.0 373.0 BLQ BLQ—Below Limit of Quantification (2.5 ng/mL)

TABLE 3 CBG concentration in rat brain tissue (Day 21). CBG concentration (ng/g) 24 hrs Dose Rat ID post Rx Average Group 1 16013783 M BLQ NA Vehicle 16013792 M BLQ 16013795 M BLQ 16013902 F BLQ NA 16013911 F BLQ 16013917 F BLQ Group 5 16013780 M BLQ NA CBG 16013785 M BLQ  10 mg/kg 16013796 M BLQ 16013903 F BLQ NA 16013916 F BLQ 16013919 F BLQ Group 6 16013776 M BLQ NA CBG 16013778 M BLQ  30 mg/kg 16013779 M BLQ 16013799 F BLQ NA 16013901 F BLQ 16013906 F 43.8 Group 7 16013781 M 53.0 540.33 CBG 16013787 M 108.0 100 mg/kg 16013788 M 1460.0 16013798 F 271.0 299.27 16013900 F 580.0 16013910 F 46.8 BLQ-Below Limit of Quantification (1.0 ng/g) NA-Not applicable

TABLE 4 CBG glucuronide concentration (expressed as CBG equivalents) in rat plasma (Day 1). Concentration (ng/mL) 15 Min 30 Min I hr 2 hr 4 hr 8 hr 24 hr Dose Rat ID post Rx post Rx post Rx post Rx post Rx post Rx post Rx Group 2 16013777 M 8150 11400 19860 43550 36500 20000 123 CBG 16013786 M 1320 22110 24420 35050 59500 32800 171 10 mg/kg 36013790 M 3220 7860 34500 80500 24650 15260 701 16013909 F 4410 15330 31800 35850 21700 6580 594 16013914 F 747 33900 55500 49600 63000 28400 316 16013918 F 2210 36600 65600 67700 55500 28000 200 Group 3 16013784 M 38950 138000 150000 124000 150000 124000 2600 CBG 16013789 M 49450 78800 34400 116000 34400 116000 748 30 mg/kg 16013791 M 78000 158000 54800 106000 54800 106000 1050 16013904 F 38950 112000 429000 132000 429000 132000 1080 16013912 F 82000 193000 349000 92800 349000 92800 1540 16013915 F 2090 129000 226000 101000 226000 101000 595 Group 4 16013782 M 90700 407000 949000 1570000 1880000 219000 2240 CBG 16013793 M 27700 443000 745000 2080000 1870000 215000 11140 100 mg/kg 16013794 M 64100 173000 102000 605000 1000000 282000 23600 16013907 F 100000 436000 1400000 66700 953000 9570000 81000 16013908 F 91900 482000 840000 83000 5700000 12800000 47350 16013913 F 14900 428000 2000000 7560000 10600000 2265000 10300

TABLE 5 CBG glucuronide concentration (expressed as CBG equivalents) in rat plasma (Day 21). Concentration (μg/mL) 15 min 30 min I hr 2 hr 4 hr 8 hr 24 hr Dose Rat ID post Rx post Rx post Rx post Rx post Rx post Rx post Rx Group 1 16013783 M BLQ Vehicle 16013792 M 16013795 M 16013902 F 16013911 F 16013917 F Group 5 16013780 M 3.07 6.12 5.67 8.34 23.40 15.10 0.08 CBG 16013785 M 3.83 14.90 21.50 30.20 45.30 5.53 0.02 10 mg/kg 16013796 M 6.11 9.34 22.40 30.50 42.10 17.60 0.04 16013903 F 7.51 55.50 25.30 50.40 79.20 28.10 0.12 16013916 F 8.39 22.50 32.90 56.80 66.50 63.50 0.12 16013919 F 8.58 29.20 10.10 5.80 11.10 23.20 0.09 Group 6 16013776 M 17.30 20.80 37.65 38.90 70.50 46.75 0.52 CBG 16013778 M 22.90 37.35 58.50 79.50 32.95 24.10 0.28 30 mg/kg 16013779 M NS 42.35 42.60 89.50 96.50 43.55 0.28 16013799 F 20.20 38.25 24.10 44.10 94.00 18.60 0.30 16013901 F 33.30 56.50 52.50 37.05 69.00 35.90 1.06 16013906 F 49.80 82.00 70.00 115.50 188.50 92.50 4.98 Group 7 16013781 M 25.40 119.50 246.50 795.00 46.70 119.00 2.20 CBG 16013787 M 20.70 80.50 178.00 241.50 390.00 141.00 2.44 100 mg/kg 16013788 M 29.70 119.50 142.50 570.00 1240.00 185.50 3.62 16013798 F 63.10 216.50 1440.00 330.00 1425.00 4250.00 20.70 16013900 F 106.00 463.00 1540.00 3905.00 5550.00 5550.00 27.00 16013910 F 127.00 432.00 453.00 830.00 1970.00 1555.00 3.79 BLQ—Below Limit of Quantification (2.5 ng/mL) NS—No sample

Example 3A. Metabolic Stability Study in Human Intestine Microsomes

The objective of this study was to investigate the stability of the test compound, CBG, in the presence of intestinal microsomes that only have UGT activity and no CYP activity.

Protocol

Test compound (1 μM) was incubated with pooled intestinal microsomes at 6 time points over the course of a 60 min assay and the test compound is analyzed by LC-MS/MS.

Microsomes (final protein concentration 0.5 mg/mL), alamethicin (25 jig/mg), 0.1 M Tris, 5 mM MgCl₂ buffer pH 7.4 and test compound (final substrate concentration 1 μM; final DMSO concentration 0.25%) were pre-incubated at 37° C. prior to the addition of UDPGA (final concentration 5 mM) to initiate the reaction. The final incubation volume is 500 μL. A minus cofactor control incubation was included for each compound tested where 0.1 M Tris, 5 mM MgCl2 buffer pH 7.4 is added instead of UDPGA (minus UDPGA). Two control compounds were included. All incubations were performed singularly for each test compound.

Each compound was incubated for 0, 5, 10, 20, 40 and 60 min. The control (minus UDPGA) was incubated for 60 min only. The reactions were stopped by transferring incubate into acetonitrile at the appropriate time points, in a 1:3 ratio. The termination plates were centrifuged at 3,000 rpm for 20 min at 4° C. to precipitate the protein.

Quantitative Analysis

Following protein precipitation, the sample supernatants were combined in cassettes of up to 4 compounds, internal standard was added and samples analysed using Cyprotex generic LC-MS/MS conditions.

Data Analysis

From a plot of ln peak area ratio (compound peak area/internal standard peak area) against time, the gradient of the line was determined. Subsequently, half-life and intrinsic clearance were calculated using the equations below:

Eliminationrateconstant(k) = (−gradient) ${{Half} - {life}\left( t_{1/2} \right)\left( \min \right)} = \frac{0.693}{k}$ ${{Intrinsic}{clearance}\left( {CL}_{int} \right)\left( {{µL}/\min/{mg}{protein}} \right)} = \frac{V \times 0.693}{t_{1/2}}$ whereV = Incubationvolume(µL)/Microsomalprotein(mg)

Results

The parent compound CBG disappeared rapidly when incubated with human intestine microsomes (see Table 6), while CBG-glucoronide appeared rapidly when incubated with human intestine microsomes (see Table 7).

These results confirm UGT glucuronidation of CBG presents a significant barrier to oral bioavailability.

TABLE 6 Metabolic Stability Assay-profile of parent compound CBG Compound Metabolic Stability (ProteinType = Microsomes + Alamethicin, ProteinSource-Intestinal, Species = Human, FinalTimePoint = 60 min, Cofactor = UDPGA, BufferType = Tris, TerminationSolution = ACN + formic, HasQCs = No, TimePoints = 6) CL_(int) (μL/min/mg SE t_(1/2) Id protein) CL_(int) (min) n Comments CBG 884 0 1.57 2 Test compound not detectable by 10 minutes. CLint calculated from 0 and 5 minute time points only. 10, 20, 40, and 60 minute time points excluded.

TABLE 7 Metabolic Stability Assay - profile of metabolite CBG glucuronide Metabolic Stability (Protein Type = Microsomes + Alamethicin, ProteinSource = Intestinal, Species = Human, FinalTimePoint = 60 min, Cofactor = UDPGA, BufferType = Tris, Parent TerminationSolution = ACN + formic, HasQCs = No, TimePoints = 6) Cmpd Metabolite Time Metabolite Formation Id Id (min) Compound Peak Area IS Peak Area Peak Area Ratio CBG Metabolite  0 46.9 615499 0.0000762 1  5 1415 628102 0.00225 10 1563 629362 0.00248 20 1869 619885 0.00301 40 1736 614702 0.00282 60 1389 561884 0.00247 Control 587897

Example 3B. Conversion of CBG and Compound 1 to Glucuronides Metabolites by Isolated UGT Isozymes

The purpose of this study was determined which Isoform of UGT was the most active with CBG, and to compare and contrast that activity with Compound 1 monomethyl ether.

Experimental Summary: UGT Reaction Phenotyping (7 Isoforms).

Test Test UGT Incubation UGT Analytical Article conc. Source Times Isozyme Method CBG 5 μM Human 0, 10, UGT1A1, LC-MS/MS recombinant 20, 40, UGT1A3, Supersomes and 60 min UGT1A4, (37° C.) UGT1A6, UGT1A9, UGT2B7,

Experimental Procedure: cDNA expressed human UGT enzyme preparations (Supersomes) supplied by BD Biosciences were obtained and stored at −80° C. prior to use. The specific isoforms were chosen by the performing laboratory based on published guidelines. They are considered the clinically relevant of the UGT isoforms (E. Kasteel et al. Human variability in isoform-specific UDP-glucuronosyltransferases: markers of acute and chronic exposure, polymorphisms and uncertainty factors. Arch Toxicol. 2020; 94(8): 2637-2661)

Supersomes in 0.1 M Tris buffer pH 7.4, alamethicin (44.6 μg/mL) and test compound (final concentration of 5 μM; final DMSO concentration ≤0.1%) were pre-incubated at 37° C. prior to the addition of UDGPA (final concentration 2 mM) to initiate the reaction. Incubations were also performed using control Supersomes (no UGT enzymes present) to reveal any non-enzymatic degradation. Compounds known to be metabolized specifically by each UGT isoform were used as control compounds (7-hydroxy-4-trifluoromethylcoumarin, all but UGT1A4, or trifluoperazine for UGT1A4).

CBG or Compound 1 were incubated in duplicate for 0, 10, 20, 40 and 60 min with each isoform. The reactions were stopped by the addition of methanol containing an analytical internal standard at the time points specified in the table above. Stopped reactions were kept on ice for at least ten minutes and the samples were centrifuged to remove precipitated protein. Supernatants were analyzed by LC-MS/MS methodology developed by the performing laboratory to quantitate the parent remaining.

As examples, the data obtained with UGT1A9 and UGT2B7 are shown in FIG. 34 . And FIG. 35 Plots of similar design were obtained with each Isoform and both test articles.

The change in CBG concentration were used to calculate the Half life (t½ in min) and the intrinsic clearance (p/min/mg) as shown in the following table (S. C, Khojasteh et. al., Drug Metabolism and Pharmacokinetics Quick Guide, Springer, N Y, 2011), Intrinsic Clearance (Clin) is a measure of the ability of hepatocytes to eliminate drug irrespective other factors such as blood flow or protein binding. The calculations were the same as those used in Example 3A.

UGT Reaction Phenotyping: data summary Recombinant UGT CL_(INT) _(ª) Recombinant Reference Compound/ Test Test UGT Clearance UGT Half Life Test Article Conc. Isoform (μl/min/mg) T_(1/2) _(b) (mins) Trifluoperazine 1 μM UGT1A4 0.70 985.85 Trifluoperazine 1 μM UGT1A4 — *6.38 Glucuronide 7-OH4trifluoromethyl- 1 μM UGT1A1 41.84 33.14 coumarin 7-OH4trifluoromethyl- 1 μM UGT1A3 26.78 51.77 coumarin 7-OH4trifluoromethyl- 1 μM UGT1A6 216.26 6.41 coumarin 7-OH4trifluoromethyl- 1 μM UGT1A9 456.07 3.04 coumarin 7-OH4trifluoromethyl- 1 μM UGT2B7 27.49 50.43 coumarin 7-OH4trifluoromethyl- 1 μM UGT2B15 55.78 24.85 coumarin CBG 1 μM UGT1A1 17.98 77.1 1 μM UGT1A3 31.43 44.11 1 μM UGT1A4 <2.89 >240 1 μM UGT1A6 14.59 95.05 1 μM UGT1A9 720.53 1.92 1 μM UGT2B7 77.54 17.88 1 μM UGT2B15 29.11 47.62 Compound 1 1 μM UGT1A1 13.48 102.8 1 μM UGT1A3 12.81 108.22 1 μM UGT1A4 <2.89 >240 1 μM UGT1A6 <2.89 >240 1 μM UGT1A9 99.10 13.99 1 μM UGT2B7 55.89 24.80 1 μM UGT2B15 24.24 57.18 ^(I)ntrinsic Clearance; ^(b)Half-Life; *average peak area ratio at 60 min/average peak area ratio at 0 min)

The enzymatic activity was as expected with the positive controls, indicating the enzymatic incubators were behaving as expected. The results demonstrate that CBG is extensively converted to the glucuronide conjugate by UGT and the highest activity was seen with isoform UGT1A9. The activity with this isoform represents close to 80% of the activity with CBG for all the UGTs combined. The second most active enzyme was UGT2B7 which was approximately 1/10 as active as UGT1A9. Both Isoforms have been shown to be present in the liver and intestine, as well as the kidney (Kassteel et. Al. 2020) In fact, some 53% of the UGT activity in the GI tract is associated with UGT2B7. These two enzymes would be responsible for most of the glucuronide formation for orally CBG.

These data are consistent with the observation that glucronidation of CBG by the GI tract is extensive, and is primarily due to the UGT1A9 and UGT2B7 Isofrom.

Activities were somewhat lower with Compound 1, the monomethyl congener of CBG. Total UGT activity was only 23% of that observed with CBG, but 73% of that activity was still associated with UGT1A9 and UGT2B7.

Example 3C. Potential for Compound 1 to Inhibit the Glucuronidation of CBG by Monomethyl CBG (CBG)

The purpose of this experiment was to determine if Compound 1 can inhibit the glucuronidation of CBG, as both are substrates for the two major isoforms responsible for CBG glucuronidation.

The ability of Compound 1 to inhibit the metabolism of CBG by UGT1A9 and UGT2B7 enzymes was investigated to ascertain the IC₅₀ values for direct inhibition. The incubation conditions (substrate concentration, incubation time and protein concentration) were determined in Part 2 of the protocol such that CBG metabolism remains near initial rate conditions (e.g., 20-30% substrate loss).

Preliminary experiments were conducted in Part I of the protocol, first to establish the HPLC/MS/MS bioanalytical methods for CBG and CBG glucuronide. The establishment of the method was routine and the method was shown to be working appropriately. The second set of preliminary experiments (Part 2), as mentioned, were conducted to optimize the incubation conditions as described above. Incubations (at 37 C) contained Tris-HCl buffer (100 mM, pH 7.7), MgCl2 (10 mM), EDTA (1 mM, pH 7.4) and UDP-glucuronic acid (UDPGA, 10 mM). CBG was added to each incubation in DMSO such that the final percent of DMSO was 1% v/v, or less. Reactions were terminated by the addition of an equal volume of stop reagent, acetonitrile containing an internal standard. The samples were centrifuged (e.g., 920 RCF for 10 minutes at 10° C.), and the supernatant fractions were analyzed by LC-MS/MS to determine the amount of CBG remaining and formation of one metabolite (CBG glucuronide).

The results of the preliminary experiments are summarized in FIG. 37 and FIG. 38 .

To examine its ability to act as a direct inhibitor of the above listed enzymes, Compound 1 was be added to recombinant human UGT enzyme together with CBG. Reactions were initiated with UDPGA and were carried out in duplicate. For all assays, reactions were terminated by the addition of acetonitrile with or without 2% v/v formic acid, including the internal standard.

Authentic metabolite reference standards were used for quantitation of the probe substrate metabolites and as internal standards. Based on the information obtained in the Part 2 experiments, the following table summarizes the experiments performed, assessing the inhibitory effects of Compound 1 was conducted as follows:

Description Test Article Positive control Substrate CBG 7-hydroxycoumarin Substrate   10 μM 1 μM Concentration Inhibitor Compound 1 NA Inhibitor 0 (solvent control), 0.01, 0.03, 0.1, 0.3, 1, 3, NA Concentration (μM) 10 Incubation volume 0.2-mL Incubation 37 ± 2° C. temperature Test systems rUGT1A9 and rUGT2B7ª rUGT1A9 Incubation   4 min 0 and 60 time (min) rUGTIA9 0.25 mg protein/ml 0.1 mg protein/mL Protein/incubation rUGT2B7 Incubation   5 min 0 and 60 time (min) rUGT2B7 0.25 mg protein/ml 0.1 mg protein/mL Protein/incubation Incubation buffer Tris-HCI buffer (100 mM, pH 7.7), MgCl2 (10 mM), EDTA (1 mM, pH 7.4) Cofactor UDPGA (10 mM)^(b) Start method Addition of co-factor Description Test Article Positive control Number of replicates  2 2 Assay determination Substrate loss with calibration curve Substrate loss without Formation of one metabolite (without calibration curve calibration curve) ^(a)Each test system will be incubated separately.

The results of these experiments are summarized below. The amounts of CBG present at the end of the incubation periods was determined. For inhibition to have occurred, the amounts of CBG present at the end of the incubation period needed to increase, and the amounts of glucuronide formed needed to decrease.

CBG loss Percent CBG detected of Test system (pmol) control rUGT1A9 10 μM CBG 1140 100 10 μM CBG + 0.01 μM 1250 109 Compound 1 10 μM CBG + 0.03 μM 1250 110 Compound 1 10 μM CBG + 0.1 μM 1280 112 Compound 1 10 μM CBG + 0.3 μM 1300 114 Compound 1 10 μM CBG + 1 μM 1210 106 Compound 1 10 μM CBG + 3 μM 1200 105 Compound 1 10 μM CBG + 10 μM 1140 99.8 Compound rUGT2B7 10 μM CBG 1330 100 10 μM CBG + 0.01 μM 1370 103 Compound 1 10 μM CBG + 0.03 μM 1460 109 Compound 1 10 μM CBG + 0.1 μM 1410 106 Compound 1 10 μM CBG + 0.3 μM 1450 109 Compound 1 10 μM CBG + 1 μM 1460 109 Compound 1 10 μM CBG + 3 μM 1440 108 Compound 1 10 μM CBG + 10 μM 1470 111 Compound 1

Glucuronide formation CBG glucuronide Percent formed of Test system (area ratio) control rUGTIA9 10 μM CBG 371000 100 10 μM CBG + 0.01 μM Compound 1 350000 94.4 10 μM CBG + 0.03 μM Compound 1 360000 97.1 10 μM CBG + 0.1 μM Compound 1 341000 92.0 10 μM CBG + 0.3 μM Compound 1 350000 94.4 10 μM CBG + 1 μM Compound 1 343000 92.6 10 μM CBG + 3 μM Compound 1 347000 93.6 10 μM CBG + 10 μM Compound 1 344000 92.8 rUGT2B7 10 μM CBG 249000 100 10 μM CBG + 0.01 μM Compound 1 260000 104 10 μM CBG + 0.03 μM Compound 1 252000 101 10 μM CBG + 0.1 μM Compound 1 257000 103 10 μM CBG + 0.3 μM Compound 1 262000 105 10 μM CBG + 1 μM Compound 1 253000 102 10 μM CBG + 3 μM Compound 1 252000 101 10 μM CBG + 10 μM Compound 1 239000 96.0

The metabolism of CBG by the two isoforms was essentially unchanged by the presence Compound 1, whether CBG disappearance or glucuronide formation was assessed. These data demonstrate that Compound 1 is not an effective inhibitor of the conversion of CBG to a glucuronide.

Example 4. Hepatocyte Stability and Metabolite Profiling Report for CBG (CBG) in Cryopreserved Hepatocytes

The objective of this study was to investigate the stability of the test compound, CBG, in human, rat, dog, mouse, monkey and minipig cryopreserved hepatocytes. Follow-on metabolite profiling was performed.

Hepatocyte Stability

CBG was incubated up to 2 hr with cryopreserved hepatocytes. Cryopreserved hepatocytes in suspension were added to test compound in supplemented media following pre-incubation to initiate the reaction and the reactions were stopped by organic solvent at the appropriate time points. The termination plates were centrifuged and sample supernatants were analysed using Cyprotex generic LC MS/MS conditions to generate intrinsic clearance values for CBG. Two control compounds for each species were included in the assay and if the values for these compounds were not within the specified limits the results were rejected and the experiment repeated.

As shown in Table 8 below CBG gave an intrinsic clearance value of 61.4 μL/min/106 cells, 28.3 μL/min/106 cells, 26.3 μL/min/106 cells, 32.8 μL/min/106 cells, 122 μL/min/106 cells and 32.5 μL/min/106 cells in cryopreserved human, rat, dog, mouse, monkey and minipig hepatocytes, respectively.

TABLE 8 Hepatocyte stability CBG data Species CL 

 (μL/min/10⁶ cells) SE CL 

 (min) n Human 61.4 12.6 22.6 5^(a) Rat 28.3 4.46 49.0 6 Dog 26.3 5.22 52.7 5^(a) Mouse 32.8 2.91 42.2 5^(a) Monkey 122 32.3 11.3 4^(b) Minipig 32.5 5.85 42.7 5^(a) n = number of concentrations used to fit curve; SE = Standard error of the curve fining: ^(a)= 120 manure time point excluded: ^(b)= 60 and 120 minute time points excluded.

indicates data missing or illegible when filed

Metabolite Profiling

Following the hepatocyte stability assay the samples were 59 tilized for metabolite profiling using suitable high-resolution LC-MS/MS conditions. The 40 and 60 minute human samples, 20 and 120 minute rat samples, 10 and 20 minute dog and monkey samples, 20 and 60 minute mouse samples, and 40 and 120 minute minipig samples were compared against the 0 minute control sample to establish which and how many metabolites were formed. The data acquired for the mouse hepatocyte samples showed instability in both the live and associated lysed samples indicating solubility and/or non-specific binding. No further analysis was carried out with the mouse species.

The areas and percentages reported for the parent and metabolites were calculated using the XIC data. Metabolite observed at greater than 1% of the total of drug related material are reported. The m/z found for each metabolite in each species, and its associated ppm error, have been displayed for each species from the time point showing the largest peak area. For accuracy, a ppm error of less than 5 is desirable; when the response for a metabolite observed is low the ppm error maybe greater than 5. Where a metabolite has been referred to as a potential oxidation it can refer to a potential hydroxylation, epoxidation or oxide formation. Representative collision induced dissociation (CID) mass spectra were obtained for the metabolites found.

In summary, a total of twelve metabolites have been found and reported. Seven, eight, three, four and four metabolites were observed in human, rat, dog, monkey and minipig hepatocyte samples respectively. These data showed that glucuronidation is the major driver of metabolism and the only metabolite seen in all species. Structural elucidation is provided for five of these metabolites, M1, M2, M4 (See FIG. 13 ), M7 and M10 (See FIG. 14 ). Structures are depicted in Markush format with the shaded area showing potential sites of modification.

Example 5: PK Study

Protocol

This study evaluated the pharmacokinetics of (E)-2-(3,7-dimethylocta-2,6-dien-1-yl)-3-methoxy-5-pentylphenol (1) and (E)-2-(3,7-dimethylocta-2,6-dien-1-yl)-1,3-dimethoxy-5-pentylbenzene (2) following oral (PO) or intraperitoneal (IP) administration to male Sprague Dawley rats. The study design is shown in the Table 9 below.

Other compounds of the present disclosure (e.g., one or more compounds of Formula (I), (II), (II), Table 1 or Table 2) may also be evaluated using this protocol.

TABLE 9 Dosing regimens of CBG, Compound 1, and Compound 2 Test Dose Conc Dose Volume Group N/Sex Article (mg/kg) (mg/mL) (mL/kg) Vehicle Route 1 7/M CBG 30 6 5 20% Maisine, PO 30% Labrasol and 50% water 2 7/M Cmpd 1 31.5 6.3 5 20% Maisine, PO 30% Labrasol and 50% water 3 7/M Cmpd 2 32.7 6.6 5 20% Maisine, PO 30% Labrasol and 50% water 4 7/M CBG 30 6 5 10% Ethanol, IP 10% Tween -20 and 80% Saline

Dose Formulation

For the oral formulation the test article was added to the appropriate amount of Maisine and stirred until uniform. Next Labrasol was added to the formulation and allowed to stir until uniform. Finally, water will be slowly added to the stirring formulation to achieve the final volume.

For the IP formulation the test article was added to the appropriate amount of ethanol and stirred until uniform. Next, the appropriate amount of tween-20 was added to the stirred formulation. Finally, the appropriate amount of saline was slowly added to the stirred formulation to achieve the final volume.

Animals were fasted the evening prior to dosing with food returned at 4 h postdose, and the animals weighed on the morning of dose administration.

Dose Administration:

IP doses were administered via injection to the intraperitoneal region. PO doses were delivered into the stomach via syringe and gavage tube.

Blood was collected from via direct jugular stick or from the tail vein. Blood samples were kept on ice until being centrifuged at 3200 RPM for 10 minutes at ˜5° C. within 1 h of collection. Plasma was split into 2 cryovials in approximately equal volumes (0.05 mLs) and stored at −20° C.±5° C. until shipment.

Results

The Plasma Concentration vs Time Profile graphs for Groups 1-4 are shown in FIGS. 1-10 . The parent compound CBG was converted by glucuronidation to CBG-glucoronide following both oral and IP administration (see FIG. 5 , FIG. 6 , FIG. 11 and FIG. 12 ). In contrast, Compound 1 showed significantly reduced levels of glucuronidation compared to CBG (see FIG. 7 and FIG. 8 ) and Compound 2 completely blocked glucuronide formation (see FIG. 9 and FIG. 10 ). Thus, both Compound 1 and Compound 2 exhibited much higher bioavailability than CBG.

Example 6. Anti-Inflammatory Activity of CBG and Derivatives in a Rat LPS Model

This assay was employed to determine the efficacies of CBG, compound 1, and compound 2 against lipopolysaccharide (LPS)-induced inflammation in Sprague Dawley rats.

Other compounds of the present disclosure (e.g., one or more compounds of Formula (I), (II), (III), Table 1 or Table 2) may also be evaluated using this protocol.

Protocol:

Eight- to 10-week-old male rats were treated with CBG, Compound 1, and Compound 2, or a positive control (cyclosporin A) for four days prior to treatment with LPS. Twenty-eight (28) Sprague Dawley male rats, 8-10 weeks old, were used for this study. Animals were randomized by weight into one of 7 treatment groups as shown in Table 10 below and treated for 4 days with either vehicle control (Groups 1 and 2), Cyclosporin A (Neoral) (Group 3), CBG at 30 mg/kg (Group 4), Compound 1 at 31.5 mg/kg (Group 5), Compound 2 at 32.7 mg/kg (Group 6) or CBG at 30 mg/kg (intraperitoneal/IP; Group 7). Groups 1-6 were dosed for 4 days by oral gavage; group 7 was dosed for 4 days by IP injection. After the 4th injection, Groups 2-7 received a single IP injection of LPS at 5 mg/kg to induce inflammation. Body weight was recorded every other day starting on the day of or day prior to the first day of treatment. A terminal body weight was recorded. General health and clinical signs were recorded once daily. Blood was collected to isolate immune cells at 2 hours after the LPS injection. Animals were humanely euthanized after blood collection. Immune cells were isolated from whole blood and supplied as a cell pellet for cytokine analysis.

TABLE 10 Dosing regimens of CBG, Compound 1, and Compound 2 Group Dosages LPS injection # Treatment (mg/kg) Vehicle Route Frequency day 4 Males 1 Vehicle N/A 20% Maisine, PO QD X 4 N/A 4 30% Labrasol and 50% water 2 Vehicle N/A 20% Maisine, PO QD X 4 5 mg/kg 4 30% Labrasol IP and 50% water 3 Cyclosporine A 70 Phosphate PO QD X 4 5 mg/kg 4 Buffered IP Saline 4 CBG 30 20% Maisine, PO QD X 4 5 mg/kg 4 30% Labrasol IP and 50% water 5 Compound 1 31.5 20% Maisine, PO QD X 4 5 mg/kg 4 30% Labrasol IP and 50% water 6 Compound 2 32.7 20% Maisine, PO QD X 4 5 mg/kg 4 30% Labrasol IP and 50% water 7 CBG 30 10% Ethanol, IP QD X 4 5 mg/kg 4 10% Tween -20, IP 80% Saline

Ex Vivo Analysis of Cytokines

Cytokines known to be pro-inflammatory and particularly involved in inflammatory bowel disease (IBD) are IL-1B, IFNy and TNFa. A study was conducted to analyze rat serum these cytokines in samples from Groups 1-7 of the study described above.

Serum samples (N=82) were processed and shipped to Inotiv Boulder for analysis. The samples were derived from twenty-eight (28) rats with a collection time point (2 h). The samples were analyzed for cytokine levels using the RECYTMAG-65K Luminex™ kit. The results of the assays are reported in FIG. 15A, FIG. 15B and FIG. 15C.

Statistical analysis: Wilcox rank sum analysis was conducted for the 2-hour time point. This type of analysis was appropriate due to the non-Gaussian nature of the data. An initial Groups 1 and 2 comparison demonstrated the LPS treatment resulted in significant changes in cytokine levels. Next, Groups 4, 5, and 6 were compared to Group 2 to determine if there were significant changes in cytokine levels as results of drug treatment. Significant differences between Group 1 and 2 were indicated by a plus sign (+) on the summary bar graphs and statistical differences for Groups 4, 5 and 6 versus group 2 were dictated by were also marked with an asterisks (*) on the bar graphs.

Results:

For IL-1B and IFNy all three orally dosed treatment groups (Groups 4-6) showed a significant reduction in the pro-inflammatory cytokines in comparison to Group 2. In both cases Compound 2 and Compound 3 performed equal to or better than CBG, indicating enhanced bioavailability may contribute to better anti-inflammatory efficacy. Although TNFa reduction was not significant there was a downward trend in the oral treatment Groups 4-6.

Example 7. Effects of Compound 1 and Compound 2 Administered in an Indomethacin-Induced Crohn's Disease in Rats

The objective of this study was to determine the efficacy of Compound 1 and Compound 2 in a model of Crohn's disease (indomethacin induced intestinal injury) in rats.

Other compounds of the present disclosure (e.g., one or more compounds of Formula (I), (II), (III), Table 1 or Table 2) may also be evaluated using this protocol.

Stud Design

The study design was identical for Compound 1 and Compound 2. On study day −3, rats were weighed and distributed into treatment groups based on body weight.

On study day 0, treatment was initiated and continue as indicated in the Study Design Tables below. Groups 2-6 received a subcutaneous injection of indomethacin (9 mg/kg, 1 ml/kg) in 5% sodium bicarbonate (Sterile Water). On study day 1, Groups 2-6 received a second subcutaneous injection of indomethacin (8 mg/kg, 1 ml/kg) in 5% sodium bicarbonate (Sterile Water). Live phase sample & data collection specifics are outlined below. On study day 4, animals will be euthanized, a section of the small intestine will be removed and weighed. Further necropsy sample and data collection is specified below. Overall efficacy of test articles will be based on body weight, small intestine weight (10 cm), small intestine gross score, and histopathology

TABLE 11 Compound 1 Study Design Table Dose Route, Dosing Group N Disease Treatment (mg/kg) Regimen Days Vehicle 1 5 No Normal N/A N/A 0-3 N/A 2 10 Yes Vehicle N/A PO 0-3 DM-P1-2 3 10 Yes Dexamethasone 0.1 PO 0-3 1% CMC 4 10 Yes Compound 1 50 PO 0-3 DM-A1-2 5 10 Yes Compound 1 200 PO 0-3 DM-A1-2 6 10 Yes Compound 1 800 PO 0-3 DM-A1-2

TABLE 12 Compound 2 Study Design Table Dose Route, Dosing Group N Disease Treatment (mg/kg) Regimen Days Vehicle 1 5 No Normal N/A N/A 0-3 N/A 2 10 Yes Vehicle N/A PO 0-3 DM-P1-2 3 10 Yes Dexamethasone 0.1 PO 0-3 1% CMC 4 10 Yes Compound 2 50 PO 0-3 DM-A1-2 5 10 Yes Compound 2 200 PO 0-3 DM-Al-2 6 10 Yes Compound 2 800 PO 0-3 DM-A1-2

At necropsy, the small intestines were evaluated visually and given a gross score according to the following criteria: 0=Normal. 0.5=Very Minimal thickening, multifocal in area at risk. 1=Minimal thickening, fairly diffuse in area at risk. 2=Mild to moderate small intestinal/mesenteric thickening throughout area at risk. 3=Moderate thickening with 1 or more definite adhesions that would be easy to separate. 4=Marked thickening with numerous hard to separate adhesions. 5=Severe intestinal lesion resulting in death.

Morphologic Pathology Methods

Preserved 9-cm sections of small intestine were trimmed into 6 transverse sections collected at approximately equal intervals along the width of the intestine, without bias toward lesion presence or absence. These trimmed sections were processed through graded alcohols and a clearing agent, infiltrated and embedded in paraffin, sectioned, and stained with hematoxylin and eosin (H&E).

Small intestine sections from all animals were examined microscopically by a board-certified veterinary pathologist, and observations were entered into a computer-assisted data retrieval system. Cross sections of small intestine were scored for inflammation and necrosis using the following criteria:

TABLE 13 Necrosis Scoring Criteria Score Observation 0 = None 0.5 = 1-499 μm width, generally <5% of mucosa affected 1 = 500-1000 μm width, generally 5-10% of mucosa affected 2 = 1001-1500 μm width, generally 11-15% of mucosa affected 3 = 1501-2000 μm width, generally 16-20% of mucosa affected 4 = 2001-3000 μm width, generally 21-25% of mucosa affected 5 = Greater than 3000 μm width >25% of mucosa affected

The area at risk for development of this lesion is generally approximately 30% of the total area of a cross section of small intestine where the mesentery attaches. The total circumference is generally about 10,000 μm and of this total, only about 4000 μm is generally at risk for lesion development, hence the low range for the % mucosa affected.

TABLE 14 Inflammation Scoring Criteria Score Observation 0 = None 0.5 = Very = Localized to mesentery, very minimal in intestine, (generally minimal associated with necrosis score of 0.5 if necrosis is present) 1 = Minimal = Diffuse in mesentery and focal in intestinal lesion if present (generally associated with necrosis score of 1, or higher necrosis scores if there is an anti-inflammatory effect in the absence of a beneficial effect on necrosis) 2 = Mild = Diffuse in mesentery and intestinal lesion (generally associated with necrosis score of 2 or higher) 3 = Moderate = Diffuse in mesentery and intestinal lesion (generally associated with necrosis score of 3 or higher) 4 = Marked = Diffuse in mesentery and intestinal lesion (generally associated with necrosis score of 4 or higher) 5 = Severe = Diffuse in mesentery and intestinal lesion (generally associated with necrosis score of 5 or higher)

Inflammation is localized to the mesentery and intestinal area at risk for necrosis with slight extension on either side of it. Therefore, the inflammation severity generally tracks with the necrosis and hence has similar scores except where necrosis occurs, and inflammation is down modulated by treatments. In this case, inflammation is scored based on overall severity ranging from 0.5 (very minimal) to 5 (severe) without regard for the extent of necrosis.

The mean score for necrosis and inflammation was calculated for each animal and these mean scores were then summed to arrive at a total score. Each section also has a measurement of total width of mucosal necrosis.

Results

The Compound 1 treatment groups all trended towards or had significant differences in preventing weight loss in comparison to the positive control dexamethasone (FIG. 16 ). All three treatment groups for Compound 1 showed significantly lower small intestine weight compared to vehicle (FIG. 17 ). Group 4 showed a trend in lower small intestine gross score while both Groups 5-6 had significant reductions in gross score compared to vehicle (FIG. 18 ).

Histopathology scores and necrosis width for all Compound 1 treatment Groups 4 and 5 trended lower than both the vehicle (Group 2) and positive control groups (Group 3) (FIG. 19 ). Compound 1 treatment in Group 5 had significantly lower histopathology scores and necrosis width than vehicle and dexamethasone (FIG. 19 and FIG. 20 ). All these data indicate that Compound 1 is a drug candidate for the treatment of Crohn's Disease.

The Compound 2 treatment groups all trended towards or had significant differences in preventing weight loss in comparison to the positive control dexamethasone and the vehicle (FIG. 21 ). All three treatment groups for Compound 2 showed significantly lower small intestine weight compared to vehicle (FIG. 22 ). Group 4 showed a trend in lower small intestine gross score while both Groups 5-6 had significant reductions in gross score compared to vehicle (FIG. 23 ).

Histopathology scores and necrosis width all Compound 2 treatment Groups 4-6 were lower than the vehicle (Group 2) (FIG. 24 and FIG. 25 ). Compound 2 treatment in Group 5 & 6 had significantly lower histopathology scores and necrosis width than vehicle and dexamethasone. Groups 5 & 6 were especially impressive in reducing the necrosis width by 99% and 96% of vehicle respectively. All these data indicate that Compound 2 is a drug candidate for the treatment of Crohn's Disease.

Example 8. GI₅₀ Assay and Target Engagement Assay of DM Compounds on Colon Cancer Cell Lines

The objective of this experiment is to screen the effect of compounds of the instant disclosure by measuring their capability to reduce the colon cancer cell viability and inhibit colony formation, and to investigate the target engagement by Western blot detection of specific protein expression under compound treatment.

Other compounds of the present disclosure (e.g., one or more compounds of Formula (I), (II), (III), Table 1 or Table 2) may also be evaluated in this assay.

ABBREVIATION DESCRIPTION nm nanometer μM micromolar mM milimolar SD Standard Deviation FBS Fetal Bovine Serum DMSO Dimethyl sulfoxide

For MTS assay, the compounds have been tested at 8 concentrations on 4 colon cancer cell lines for 48 hours. The compounds, concentrations and colon cancer cell line panel tested are the following:

CBG: 0 μM, 1.25 μM, 2.5 μM, 5 μM, 10 μM, 20 μM, 40 μM, and 80 μM.

Compound 1: 0 μM, 1.25 μM, 2.5 μM, 5 μM, 10 μM, 20 μM, 40 μM, and 80 μM.

Compound 2: 0 μM, 1.25 μM, 2.5 μM, 5 μM, 10 μM, 20 μM, 40 μM, and 80 μM.

Colon cancer cell line panel: SW620, HCT15, HT29, HCT116

For colonogenic assay, the compounds were tested at 4 concentrations for 1 week or 2 weeks on 4 colon cancer cell lines. The compounds, concentrations, colon cancer cell line panel and end time point tested are the following:

CBG: 0 μM, 10 μM, 20 μM, 40 μM, and 80 μM.

Compound 1: 0 μM, 5 μM, 7.5 μM, 10 μM, and 20 μM.

Compound 2: 0 μM, 10 μM, 20 μM, 40 μM, and 80 μM.

Colon cancer cell line panel and end time point: SW620, HCT15, HCT116, 1 week; HT29, 2 weeks

For Western blot, the compounds were tested at 4 concentrations for 3 hours on 3 colon cancer cell lines. The compounds, concentrations, colon cancer cell line panel, and antibodies panel tested are the following:

CBG: 0 μM, 10 μM, 20 μM, 40 μM, and 80 μM.

Compound 1: 0 μM, 10 μM, 20 μM, 40 μM, and 80 μM.

Compound 2: 0 μM, 10 μM, 20 μM, 40 μM, and 80 μM.

Colon cancer cell line panel: SW620, HCT15, HCT116

Antibodies panel: p-cMYC(S62), cMyc, p-AKT(S473), AKT, p-ERK(T202/Y204), ERK

Methods

Four colon cancer cell lines of SW620, HCT15, HT29, and HCT116 were included in the colon cancer cell line panel.

CBG, compound 1 and compound 2 were dissolved in DMSO at a concentration of 10 mM and stored at −20° C.

Evaluation of DM compounds treatment-induced growth inhibition was performed to determine the GI50 of four colon cancer cell lines with MTS assay or clonogenic assay. Each experiment was repeated in triplicate. In GraphPad Prism, data were log-transformed and fit with a nonlinear curve to calculate the GI₅₀.

Evaluation of target engagement was performed to determine the expression of specific marker protein expression and underlying signaling pathways with Western blot.

MTS assay. cells were plated at 96 well plates at a density of 1,000 cells per well. After 24 hours, cells were treated with DM compounds at increasing concentrations or DMSO vehicle and incubated for 48 hours. 20 μl of MTS reagent (Promega) was then added and incubated for 2 hours. The absorbance was measured with a microplate reader at 490 nm. Each experiment was repeated in triplicate. In GraphPad Prism, data were log-transformed and fit with a nonlinear curve to calculate the GI₅₀.

Clonogenic assay. cells were plated at 6 well plates at a density of 2,500 cells per well. After 24 hours, cells were treated with DM compounds at increasing concentrations or DMSO vehicle and incubated for 1 week or 2 weeks. Cells were then fixed and stained with 1% crystal violet (Sigma-Aldrich) solution. Quantification was performed using ImageJ. Each experiment was repeated in triplicate. In GraphPad Prism, data were log-transformed and fit with a nonlinear curve to calculate the GI₅₀.

Western blot. Whole cell extracts were prepared by incubating cell pellets in IP lysis buffer supplemented with protease and phosphatase inhibitors (Roche). Isolated protein was quantified by Pierce BCA Protein assay (ThermoFisher). Equal quantities of protein were separated by 4-15% SDS-PAGE electrophoresis gels and transferred onto nitrocellulose membranes. Membranes was blocked with 5% nonfat milk in Tris-buffered saline-Tween buffer. The membrane were probed with the antibodies specific for p-ERK(T202/Y204) (Cell Signaling Technologies), ERK (Cell Signaling Technologies), p-AKT(S473) (Cell Signaling Technologies), AKT (Cell Signaling Technologies), p-cMyc(S62) (Abcam), cMyc (Santa Cruz Biotechnology), and Vinculin (Santa Cruz Biotechnology).

Results

Evaluation of compounds of the disclosure for treatment-induced loss of viability was performed to determine the GI₅₀ of four colon cancer cell lines with MTS assay or clonogenic assay.

Measured by MTS assay, the GI₅₀ of the CBG, compound 1, and Compound 2 on SW620 cells was 39.98±0.84, 8.76±1.38, and >80 μM respectively; the GI₅₀ of CBG, compound 1, and Compound 2 on HCT15 cells was 43.56±5.74, 10.01±0.52, and >80 μM respectively; the GI₅₀ of CBG, compound 1, and Compound 2 on HT29 cells was 43.58±4.02, 10.17±0.40, and >80 μM respectively; the GI₅₀ of CBG, compound 1, and Compound 2 on HCT116 cells was 41.41±1.87, 10.30±0.24, and >80 μM respectively (Table 5).

TABLE 15 GI₅₀ (μM) of testcompounds measured with MTS assay. Cell line Compound N1 N2 N3 AVG SD SW620 CBG 39.51 39.42 38.02 38.98 0.84 Cmpd 1 8.47 7.55 10.26  8.76 1.38 Cmpd 2 >80 >80 >80 N/A N/A HCT15 CBG 50.17 30.18 40.69 43.56 5.74 Cmpd 1 10.08 9.46 10.50 10.01 0.52 Cmpd 2 >80 >80 >80 35.89 8.95 HT29 CBG 42.61 48.00 40.13 43.58 4.02 Cmpd 1 9.84 10.06 10.62 10.17 0.40 Cmpd 2 >80 >80 >80 N/A N/A HCT116 CBG 39.97 44.05 40.20 41.41 1.87 Cmpd1 10.50 9.96 10.45 10.30 0.24 Cmpd 2 >80 >80 >80 N/A N/A

Measured by clonogenic assay, the GI₅₀ of the compound of CBG, Compound 1, and Compound 2 on SW620 cells was 20.58±1.95, 5.35±1.11, and 41.66±5.90 μM respectively; the GI₅₀ of the compound of CBG, Compound 1, and Compound 2 on HCT15 cells was 17.40±2.89, 5.03±2.16, and 35.89±8.95 μM respectively; the GI₅₀ of the compound of CBG, Compound 1, and Compound 2 on HT29 cells was 9.09±1.71, 2.95±1.41, and 34.47±14.42 μM respectively; the GI₅₀ of the compound of CBG, Compound 1, and Compound 2 on HCT116 cells was 17.41±4.91, 5.51±1.51, and 43.06±7.68 μM respectively (FIG. 26 and Table 16).

TABLE 16 GI₅₀ (μM) of test compounds measured with clonogenic assay. Cell line Compound N1 N2 N3 AVG SD SW620 CBG 18.94 22.73 20.07 20.58 1.95 Cmpd 1 5.76 4.09 6.20 5.35 1.11 Cmpd 2 47.78 41.18 36.01 41.66 5.90 HCT15 CBG 15.61 20.74 15.86 17.40 2.89 Cmpd 1 3.64 7.52 3.94 5.03 2.16 Cmpd 2 46.22 30.46 31.00 35.89 8.95 HT29 CBG 8.11 8.09 11.07 9.09 1.71 Cmpd 1 1.33 3.87 3.66 2.95 1.41 Cmpd 2 51.07 25.04 27.31 34.47 14.42 HCT116 CBG 21.07 20.68 10.47 17.41 4.91 Cmpd 1 4.79 7.61 4.12 5.51 1.51 Cmpd 2 53.44 40.65 35.10 43.06 7.68

Conclusion

Among the three compounds, Compound 1 showed the most potent effect on colon cancer cell viability with the lowest GI₅₀ measured. Compounds of the disclosure down-regulated the expression of p-cMyc(S62) and cMyc in dose-dependent manner in all three colon cancer cell lines examined (FIGS. 27A-D). Compound 1 down-regulated pAKT(S473) in HCT116 cells with a dose effect (FIG. 27D).

Example 9. Study of CBD and CBD Derivative in a PTZ-Induced Epilepsy Mouse Model

Other compounds of the present disclosure (e.g., one or more compounds of Formula (I), (II), (III), Table 1 or Table 2) may also be evaluated in this assay.

Introduction and Background

Mouse models using GABA_(a) receptor antagonist Pentylenetetrazol (PTZ) are well defined and used as a standard for the identification of potential anticonvulsants to treat generalized clonic seizures (Loscher et al., 1991 Epilepsy Res 8:171-189). The purpose of this study was to evaluate and compare CBD to test article Compound 3, on their therapeutic effects in a mouse model of PTZ-induced seizure. To match up test article plasma concentration time max (Tmax) with the PTZ induced seizures; test articles were administered at 60 minutes and 30 minutes prior to PTZ administration respectively. Vehicle used for treatment groups was 10% EtOH/10% Tween 80/80% Saline.

Abbreviations Used

IP: Intraperitoneal route of administration

mg/kg: Milligrams/kilogram

mpk: Milligrams/kilogram

mg/mL: Milligrams/milliliter

mL/kg: Milliliters/kilogram

PTZ: Pentylenetetrazol

SEM: Standard error of the mean

T0: Time of PTZ administration

Study Design Table GROUP GROUP PRE- EVALUATIONS/ # TREATMENT SIZE PTZ TREAT DOSE ROUTE ENDPOINTS 1 Sham 5 N/A T0 N/A IP Modified Racme scale (Vehicle/Vehicle) for seizure severity 2 Vehicle/PTZ 10 80 mg/kg T0 N/A Measure % tonic-clonic 3 CBD/PTZ 60 min pre-PTZ 100 mg/kg Measure % mortality 4 Compd 3/PTZ 30 min pre-PTZ 100 mg/kg Terminal blood collection

PTZ Model

Mice were acclimated to the procedure room for at least 30 minutes. Pentylenetetrazole (PTZ; Sigma Aldrich) was formulated in water to a concentration of 16 mg/mL. Injections of PTZ were made at a volume of 5 mL/kg to produce a final dose of 80 mg/kg. Immediately following PTZ administration, animals were observed in real-time for 30 minutes and latency of clonic and tonic hindlimb extensor responses was recorded, as well as modified Racine Scale scoring.

Modified Racine Scale Scoring

Following PTZ administration, animals were observed for 30 mins where time to initial

seizure sign, time to clonic, and time to tonic hindlimb seizure were recorded. A 30-

minute maximum latency to seizure was imposed.

Clinical behavior was scored using the following adapted Racine scale:

Score 0, no seizures observed

Score 1, Behavioral arrest (freezing, fixed gaze, staring), vibrissae twitching,

mouth or facial clonus

Score 2, Pop or jump, straub tail, foot splay, head nodding

Score 3, Forelimb clonus, extended forelimbs, multiple pops or jerks

Score 4, Rearing and bilateral forelimb clonus, Running and running/bouncing

Score 5, All limb clonus, rearing and falling (stay fallen on rear side)

Score 6, Tonic hindlimb extensions, cardiac arrest

Behavior was scored by an observer blind to treatment. The highest score reached during every 5 minute period during the 30 minutes after PTZ was administered was recorded. Additionally, the percent tonic-clonic (number of animals progressing to the highest seizure score), and percent mortality was also calculated.

Results

FIG. 28 . Latency to First Seizure Event. The time to the first seizure event was recorded. PTZ yielded a significant decrease in latency to the first seizure compared to the vehicle/vehicle group (p≤0.0001). Data are presented as means±SEM (n=10 except Veh/Veh n=5). Statistical analysis was by Fisher's LSD test compared to Veh/PTZ group. ****p≤0.0001

FIG. 29 . Latency to Clonic Seizure Event. The time to the first clonic seizure event was recorded. PTZ yielded a significant decrease in latency to the first clonic seizure compared to the vehicle/vehicle group (p≤0.0001). Data are presented as means±SEM (n=10 except Veh/Veh n=5). Statistical analysis was by Fisher's LSD test compared to Veh/PTZ group. ****p≤0.0001

FIG. 30 . Latency to Tonic Seizure Event. The time to the first tonic seizure event was recorded. PTZ yielded a significant decrease in latency to the first tonic seizure compared to the vehicle/vehicle group (p≤0.05). Administration of CBD prior to PTZ did not yield a significantly different latency compared to PTZ alone. However, administration of Compound 3 prior to PTZ (100 mg/kg; 30 minutes prior to PTZ) did yield a significantly longer latency compared to PTZ alone p≤0.05). Data are presented as means±SEM (n=10 except Veh/Veh n=5). Statistical analysis was by Fisher's LSD test compared to Veh/PTZ group. *p≤0.05

FIG. 31 Racine scores over 5 minute intervals for 30 minutes. Following PTZ administration clinical scores (Racine scores) were recorded for each animal every 5 minutes over a 30 minute period. Compared to the vehicle/vehicle group, administration of PTZ (Veh/PTZ group) yielded an immediate and sustained significant increase in clinical score over the entire 30 minute period. (p≤0.0001). CBD (100 mg/kg; 60 minutes prior to PTZ) did not yield a significant change in clinical score compared to PTZ alone. Compound 3 (100 mg/kg; 30 minutes prior to PTZ) exhibited a significant improvement in Racine scores beginning at the 10 minute time point (p≤0.01) with this effect size maintained through to 25 minutes and improving at 30 minutes (p≤0.001). Data are presented as means±SEM (n=10). Statistical analysis was by Fisher's LSD test compared to Veh/PTZ group. **p≤0.01, ***p≤0.001, ****p≤0.0001

FIG. 32 Percent of animals reaching Tonic-clonic Stage 6. The proportion of animals in each treatment group which reached tonic-clonic Stage 6 was recorded. PTZ yielded a significant increase in proportion of animals reaching Stage 6 compared to the vehicle/vehicle group (p≤0.01). Administration of CBD prior to PTZ did not yield a significantly difference in proportion compared to PTZ alone. However, administration of Compound 3 prior to PTZ (100 mg/kg; 30 minutes prior to PTZ) did yield a significantly lower proportion compared to PTZ alone p≤0.05). Data are presented as means±SEM (n=10 except Veh/Veh n=5). Statistical analysis was by Fisher's LSD test compared to Veh/PTZ group. *p≤0.05, **p≤0.01

FIG. 33 Survival Effects. During the 30 minute observation period following PTZ administration any deaths that occurred were noted and the time to death was recorded. No deaths occurred among 5 animals receiving vehicle/vehicle compared to 9/10 deaths among vehicle/PTZ animals (p≤0.01). Compared to the vehicle/PTZ group, administration of CBD prior to PTZ did not yield a significantly reduced mortality rate. Administration of Compound 3 (100 mg/kg; 30 minutes prior to PTZ) did result in a significantly reduced mortality rate compared to the vehicle/PTZ group (p≤0.01). Data are presented as means±SEM (n=10 except vehicle/vehicle n=5). Statistical analysis was by Fisher's LSD test compared to Veh/PTZ group. **p≤0.01.

Summary of the Results

Latency to First Seizure Event.

-   -   PTZ yielded a significant decrease in latency to the first         seizure event compared to the vehicle/vehicle group (p≤0.0001).     -   As expected, administration of CBD did not result in a         difference in latency to first seizure compared to PTZ alone         (Jones et al (2010) J. Pharmacology and Experimental         Therapeutics. Vol. 332, No. 2). However, Compound 3 trended         towards a longer latency than PTZ alone, although the difference         was not significant.

Latency to Clonic Seizure Event.

-   -   PTZ yielded a significant decrease in latency to the first         clonic seizure compared to the vehicle/vehicle group (p≤0.0001).     -   Administration of CBD or Compound 3 prior to PTZ did not yield a         significantly different latency compared to PTZ alone. However,         Compound 3 had a strong trend toward longer latency for this         score.

Latency to Tonic Seizure Event.

-   -   PTZ yielded a significant decrease in latency to the first tonic         seizure compared to the vehicle/vehicle group (p≤0.05).     -   Administration of CBD prior to PTZ did not yield a significantly         different latency compared to PTZ alone.     -   Administration of Compound 3 prior to PTZ (100 mg/kg; 30 minutes         prior to PTZ) did yield a significantly longer latency compared         to PTZ alone p≤0.05).

Racine Scores

-   -   PTZ yielded an immediate and sustained significant increase in         clinical score over the entire 30 minute period compared to the         vehicle/vehicle group. (p≤0.0001).     -   CBD (100 mg/kg; 60 minutes prior to PTZ) did not yield a         significant change in clinical score compared to PTZ alone.     -   Compound 3 (100 mg/kg; 30 minutes prior to PTZ) exhibited a         significant improvement in Racine scores beginning at the 10         minute time point (p≤0.01) with this effect size maintained         through to 25 minutes and improving at 30 minutes (p≤0.001).

Percent of Animals Reaching Tonic-Clonic Stage 6.

-   -   PTZ yielded a significant increase in proportion of animals         reaching Stage 6 compared to the vehicle/vehicle group (p≤0.01).     -   Administration of CBD prior to PTZ did not yield a significant         difference in proportion compared to PTZ alone.     -   Administration of Compound 3 prior to PTZ (100 mg/kg; 30 minutes         prior to PTZ) yielded a significantly lower proportion compared         to PTZ alone p≤0.05).

Survival Effects.

-   -   PTZ administration resulted in a significant increase in the         proportion of animals that died within 30 minutes following         administration (p≤0.01).     -   CBD prior to PTZ did not yield a significantly reduced mortality         rate compared to the vehicle/PTZ group.     -   Compound 3 (100 mg/kg; 30 minutes prior to PTZ) resulted in a         significantly reduced mortality rate compared to the vehicle/PTZ         group (p≤0.01)

In summary, Compound 3 demonstrated clear anti-epileptic therapeutic activity and outperform CBD (CBD) an FDA approved drug for the treatment of epilepsy disorders (Epidiolex®) in a gold standard PTZ seizure model.

Example 10. Synthesis of (E)-2-(3,7-dimethylocta-2,6-dien-1-yl)-3-ethoxy-5-pentylphenol (Compound 4) and (E)-2-(3,7-dimethylocta-2,6-dien-1-yl)-1,3-diethoxy-5-pentylbenzene (Compound 5)

A 250 mL single neck round bottom flask was charged with CBG (8.0 g, 25 mmol), DMF (60 mL), pulverized K₂CO₃ (6.3 g; 46 mmol) and were stirred at room temperature for 15 minutes. To this solution ethyl iodide (3.9 g; 25 mmol) was added, the reaction mixture was stirred at room temperature for 16 h. The reaction was monitored by TLC (5% ethyl acetate in heptane). Two scoops of Celite were added into the reaction mixture and stirred for 10 min before the resultant mixture was filtered through a short plug of celite to remove all the insoluble. The celite bed was washed with ethyl acetate (100 mL×3) for maximum recovery. The resultant organic layer was washed with water (100 mL×5), followed by a brine wash (50 mL×2). The organic solvent was dried over Na₂SO₄ and was concentrated to receive 8.92 g of dark brown oil. The crude oil was purified by automated flash chromatography using Teledyne ISCO. Elution with just heptane afforded pure Compound 5 (1.7 g, 4.6 mmol, 18% yield) as colorless oil, purity >95% by ¹H-NMR Further elution with 0-1-% ethyl acetate in heptane provided Compound 4 (1.7 g, 4.8 mmol, 20% yield) as orange oil, purity >95% by ¹H-NMR.

Compound 4: ¹H NMR (300 MHz, CDCl₃): δ ppm 0.89 (t, J=7.12 Hz, 3H), 1.31-1.41 (m, 7H), 1.58 (s, 3H), 1.66 (s, 3H), 1.78 (s, 3H), 2.02-2.09 (m, 4H), 2.51 (t, J=7.50 Hz, 2H), 3.41 (d, J=7.20 Hz, 2H), 4.0 (q, J=7.20 Hz, 2H), 5.05 (t, J=6.30 Hz, 1H), 5.26 (m, 2H), 6.29 (d, J=6.30 Hz, 2H).

Compound 5: ¹H NMR (300 MHz, CDCl₃). δ ppm 0.93 (t, J=7.20 Hz, 3H), 1.33-1.45 (m, 9H), 1.61-1.68 (m, 8H), 1.81 (s, 3H), 1.98-2.11 (m, 4H), 2.56 (t, J=7.65 Hz, 2H), 3.38 (d, J=7.80 Hz, 2H), 4.04 (q, J=6.9 Hz, 4H), 5.12 (t, J=6.90, 1H), 5.28 (t, J=6.90 Hz, 1H), 6.37 (s, 2H).

Example 11. Synthesis of (E)-2-(3,7-dimethylocta-2,6-dien-1-yl)-5-pentyl-3-propoxyphenol (Compound 6) and (E)-2-(3,7-dimethylocta-2,6-dien-1-yl)-5-pentyl-1,3-dipropoxybenzene (Compound 7)

A 200 mL single neck round bottom flask was charged with CBG (8.0 g, 25 mmol), DMF (60 mL), pulverized K₂CO₃ (6.3 g; 46 mmol) and were stirred at room temperature for 15 minutes. To this solution 1-bromopropane (3.1 g; 25 mmol) was added, the reaction mixture was stirred at room temperature for 16 h. The reaction was monitored by TLC (5% ethyl acetate in heptane). The reaction mixture was filtered through a pad of celite to remove all the insoluble. The celite bed was washed with ethyl acetate (100 mL×3) for maximum recovery. The resultant organic layer was washed with water (100 mL×5), followed by a brine wash (50 mL×2). The organic solvent was dried over Na₂SO₄ and was concentrated to a crude brown oil. The crude oil was purified by automated flash chromatography using Teledyne ISCO. Elution with Just EtOAc/heptane (0-1%) afforded pure Compound 6 (1.7 g, 18% yield) as a light yellow oil, purity >95% by ¹H-NMR and Compound 7 (2.0 g, 19% yield) as a colorless oil, purity >95% by ¹H-NMR.

Compound 6: ¹H NMR (300 MHz, CDCl₃): δ ppm 0.88 (t, J=7.12 Hz, 3H), 1.04 (t, J=7.20 Hz, 3H), 1.29-1.34 (m, 4H), 1.51-1.84 (m, 4H), 1.58 (s, 3H), 1.66 (s, 3H), 1.80 (s, 3H), 2.02-2.09 (m, 4H), 2.46 (t, J=7.35 Hz, 2H), 3.39 (d, J=7.2 Hz, 2H), 3.89 (t, J=6.3 Hz, 2H), 5.05 (t, J=8.85 Hz, 1H), 5.21 (s, OH), 5.25 (t, J=6.45 Hz, 1H), 6.28 (s, 1H), 6.30 (s, 1H)

Compound 7: ¹H NMR (300 MHz, CDCl₃): δ ppm 0.90 (t, J=7.05 Hz, 3H), 1.05 (t, J=7.35, 6H), 1.31-1.37 (m, 4H), 1.56-1.86 (m, 6H), 1.57 (s, 3H), 1.65 (s, 3H), 1.77 (s, 3H), 1.92-2.07 (m, 4H), 2.54 (t, J=7.80 Hz, 2H), 3.36 (d, J=6.90 Hz, 2H), 3.91 (t, J=6.45 Hz, 4H), 5.09 (t, J=6.50, 1H), 5.25 (t, J=6.45 Hz, 1H), 6.34 (s, 2H).

Example 12. Synthesis of (E)-3-butoxy-2-(3,7-dimethylocta-2,6-dien-1-yl)-5-pentylphenol (Compound 8) and (E)-1,3-dibutoxy-2-(3,7-dimethylocta-2,6-dien-1-yl)-5-pentylbenzene (Compound 9)

A 250 mL single neck round bottom flask was charged with CBG (10.0 g, 31.6 mmol), DMF (100 mL), pulverized K₂CO₃ (7.86 g; 56.9 mmol) and were stirred at room temperature for 15 minutes. To this solution Bromobutane (4.33 g, 31.6 mmol) was added, the reaction mixture was stirred at room temperature for 24 h. The reaction was monitored by TLC (5% ethyl acetate in heptane). Celite were added into the reaction mixture and stirred for 10 min before the resultant mixture was filtered through a short plug of celite to remove all the insoluble. The celite bed was washed with ethyl acetate (200 mL×2) for maximum recovery. The resultant organic layer was washed with water (200 mL×4), followed by a brine wash (100 mL×2). The organic solvent was dried over anh. Na₂SO₄ and was concentrated to receive 12.5 g of dark brown oil. The crude oil was purified by automated flash chromatography using Teledyne ISCO. Elution with just heptane afforded pure Compound 9 (1.2 g, 16% yield) as colorless oil, purity >95% by ¹H-NMR. Further elution with 0-1-% ethyl acetate in heptane provided Compound 8, it needed further purification. One more column purification was attempted with 0-1-% ethyl acetate in heptane provided Compound 8 (1.0 g, 10% yield) as light brown oil, purity 93% by ¹H-NMR.

Compound 8: ¹H NMR (300 MHz, CDCl₃): δ ppm 0.89 (t, J=4.65 Hz, 3H), 0.97 (t, J=7.2 Hz, 3H), 1.29-1.37 (m, 4H), 1.44-1.65 (m, 6H), 1.67 (s, 3H), 1.71-1.80 (m, 6H), 2.01-2.10 (m, 4H), 2.50 (t, J=7.65 Hz, 2H), 3.40 (d, J=6.9 Hz, 2H), 3.94 (t, J=6.45 Hz, 2H), 5.06 (t, J=6.15 Hz, 1H), 5.21 (s, OH), 5.25 (t, J=7.2 Hz, 1H), 6.30 (s, 1H), 6.31 (s, 1H)

Compound 9: ¹H NMR (300 MHz, CDCl₃): δ ppm 0.91 (t, J=5.25 Hz, 3H), 0.97 (t, J=7.35 Hz, 6H), 1.31-1.36 (m, 4H), 1.45-1.63 (m, 8H), 1.66 (s, 3H), 1.72-1.81 (m, 8H), 1.92-2.07 (m, 4H), 2.54 (t, J=7.5 Hz, 2H), 3.35 (d, J=6.9 Hz, 2H), 3.95 (t, J=6.15 Hz, 4H), 5.09 (t, J=7.05, 1H), 5.24 (t, J=7.05 Hz, 1H), 5.34 (s, 2H)

Example 13. Synthesis of (E)-3-(allyloxy)-2-(3,7-dimethylocta-2,6-dien-1-yl)-5-pentylphenol (Compound 10) and (E)-1,3-bis(allyloxy)-2-(3,7-dimethylocta-2,6-dien-1-yl)-5-pentylbenzene (Compound 11)

A 250 mL single neck round bottom flask was charged with CBG (8.0 g, 25 mmol), DMF (60 mL), pulverized K₂CO₃ (6.3 g; 46 mmol) and were stirred at room temperature for 15 minutes. To this solution allyl bromide (3.1 g, 2.2 mL, 25 mmol) was added, the reaction mixture was stirred at room temperature for 16 h. The reaction was monitored by TLC (5% ethyl acetate in heptane). Two scoops of Celite were added into the reaction mixture and stirred for 10 min before the resultant mixture was filtered through a short plug of celite to remove all the insoluble. The celite bed was washed with ethyl acetate (100 mL×3) for maximum recovery. The resultant organic layer was washed with water (100 mL×5), followed by a brine wash (50 mL×2). The organic solvent was dried over anh. Na₂SO₄ and was concentrated to receive 9.03 g of dark brown oil. The crude oil was purified by automated flash chromatography using Teledyne ISCO. Elution with just heptane afforded pure Compound 11 (2.3 g, 5.8 mmol, 23% yield) as colorless oil, purity >98% by ¹H-NMR. Further elution with 0-1-% ethyl acetate in heptane provided Compound 10, it needed further purification. One more column purification was attempted with 0-1-% ethyl acetate in heptane provided Compound 10 (1.75 g, 4.9 mmol, 19% yield) as orange oil, purity 90% by ¹H-NMR.

Compound 10: ¹H NMR (300 MHz, CDCl₃): δ ppm 0.89 (t, J=4.8 Hz, 3H), 1.25-1.35 (m, 6H), 1.52-1.67 (m, 12H), 1.66 (s, 3H), 1.79 (s, 3H), 2.01-2.10 (m, 4H), 2.50 (dd, J=7.50 Hz, 2H), 3.41 (d, J=6.90 Hz, 2H), 4.51 (q, J=5.40 Hz, 2H), 5.07 (m, 1H), 5.23-5.28 (m, 3H), 5.36-5.44 (m, 1H), 5.99-6.1 (m, 1H), 6.30 (s, 1H), 6.33 (s, 1H)

Compound 11: ¹H NMR (300 MHz, CDCl₃): δ ppm 0.89 (t, J=7.20 Hz, 3H), 1.30-1.40 (m, 4H), 1.51-1.67 (m, 10H), 1.80 (s, 3H), 1.95-2.08 (m, 4H), 2.56 (t, J=7.65 Hz, 2H), 3.38 (d, J=7.80 Hz, 2H), 4.51 (q, J=6.9 Hz, 4H), 5.06-5.10 (m, 2H), 5.22-5.30 (m, 2H), 5.41-5.48 (m, 2H), 5.98-6.10 (m, 2H), 6.37 (s, 2H).

Example 14. Synthesis of (E)-2-(3,7-dimethylocta-2,6-dien-1-yl)-3-(2-hydroxyethoxy)-5-pentylphenol (Compound 12) and (E)-2,2′-((2-(3,7-dimethylocta-2,6-dien-1-yl)-5-pentyl-1,3-phenylene)bis(oxy))bis(ethan-1-ol) (Compound 13)

A 200 mL single neck round bottom flask was charged with CBG (10.0 g, 31.6 mmol), DMF (100 mL), pulverized K₂CO₃ (7.86 g; 56.9 mmol) and were stirred at room temperature for 15 minutes. To this solution 2-bromethan-1-ol (3.91 g, 2.2 mL, 31.6 mmol) was added, the reaction mixture was stirred at room temperature for 16 h. The reaction was monitored by TLC (20% ethyl acetate in heptane), which indicates the predominance of unreacted starting material. The reaction was then heated to 120° C. for an additional 16 hours. TLC analysis again shows incomplete conversion to the desired products. Additional K₂CO₃ (2.18 g, 15.8 mmol) and 2-bromethan-1-ol (1.97 g, 15.8 mmol) were added to the reaction, which was stirred for an additional 16 hours at 120° C. The reaction was cooled and the resultant mixture was filtered through a short plug of celite to remove all the insoluble material. The celite bed was washed with ethyl acetate (100 mL×3) for maximum recovery. The resultant organic layer was washed with water (100 mL×5), followed by a brine wash (50 mL×2). The organic solvent was dried over anhydrous Na₂SO₄ and was concentrated to yield approximately 10 grams of a dark brown oil. The crude oil was purified by automated flash chromatography using Teledyne ISCO, eluting with 0-20% EtOAc/heptane to furnish as light orange solid Compound 12 (1.25 g, 3.3 mmol, 10% yield), purity >95% by ¹H-NMR and as a dark brown oil Compound 13 (0.75 g, 1.8 mmol, 5.6/o yield), purity >95% by ¹H-NMR

Compound 12: ¹H NMR (300 MHz, CDCl₃): δ ppm 0.89 (t, J=7.05 Hz, 3H), 1.28-1.34 (m, 4H), 1.53-1.59 (m, 5H), 1.67 (s, 3H), 1.80 (s, 3H), 2.00-2.10 (m, 4H), 2.50 (t, J=7.95 Hz, 2H), 3.39 (d, J=7.20 Hz, 2H), 3.92-3.97 (m, 2H), 4.07 (t, J=4.35 Hz, 2H), 5.05 (t, J=6.3 Hz, 1H), 5.21 (s, OH), 5.22 (t, J=6.0 Hz, 1H), 6.31 (s, 1H), 6.34 (s, 1H).

Compound 13: ¹H NMR (300 MHz, CDCl₃): δ ppm 0.90 (t, J=6.75 Hz, 3H), 1.26-1.37 (m, 4H), 1.55-1.64 (m, 8H), 1.78 (s, 3H), 1.94-2.11 (m, 4H), 2.54 (t, J=7.95 Hz, 2H), 3.36 (d, J=7.20 Hz, 2H), 3.92-3.93 (m, 4H), 4.08 (t, J=4.35 Hz, 4H), 5.06 (t, J=6.45 Hz, 1H), 5.15 (t, J=6.6, 1H), 6.38 (s, 2H).

Example 15. Synthesis of Intermediate A

A suspension of hexyl triphenyl phosphonium bromide (500.0 g, 1.1 eq. 1.17 mol) was made in THF (3.4 L). The reaction mixture was cooled to −10° C. To this was added NaHMDS (215.0 g, 1.1 eq, 1.17 mol) dropwise maintaining temperature below 0° C. The solution turned bright yellow-orange suspension. The reaction mixture was stirred at 0° C. for one hour. To this mixture, aldehyde (339.0 g, 1.0 eq, 1.06 mol) dissolved in THF (650 mL) was added slowly maintaining the temperature below 5° C. Upon addition, the reaction mixture was slowly warmed to room temperature and left stirring overnight. After 17 hours, TLC confirms total conversion by absence of aldehyde.

The mixture was diluted with water (2.0 L) and ethyl acetate (2.0 L), separated the layers, organic phase was washed with water (4×2.0 L) and brine (1.0 L), dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure to get 378 gr crude compound. Took a wide mouth cintered funnel. 9″ wide and 12″ Long. Filled silica gel until 9″. Eluted with 5 L Heptane—No product eluted out. Eluted with 5 L 10% Ethyl acetate in heptane—No product eluted. Eluted with 10 L 10% ethyl acetate in heptane—The product eluted out. Another 5 L 10% ethyl acetate in heptane—Dark yellow eluent came out—No product. Pooled all the fractions containing product. Concentrated under reduced pressure. Dried under high vacuum and obtained 321 gr of pure product.

To a suspension of Pd/C (20.0 g, 0.33 eq, 169.0 mmol) in DCM was added compound 2 (196.0 g, 1.0 eq, 507.1 mmol) into the 2 L autoclave. To the mixture was added methanol and ethyl acetate (1.4 L) in 1:1 ratio. The Autoclave vessel is capped tightly. The hydrogen is passed into the vessel. bubbled at 50 psi. stirred for 5 min and the pressure was vented out to remove any dissolved oxygen. This procedure was done thrice to ensure complete removal of the dissolved oxygen. The autoclave was maintained at pressure of 100 psi and stirred overnight. After completion of the reaction by TLC and LCMS solids were filtered off using a pad of celite. The pad was washed with ethyl acetate (500 mL) and the filtrate was concentrated. This reaction mixture was combined with batch SP-000095-CAR-0021. The total reaction mixture from two batches was combined and dissolved in 1.0 L DCM. To this was added 200 grams of activated carbon along with 400 grams of silica gel. The suspension was stirred overnight stirred and Silica gel/Carbon was filtered off using a pad of celite. The filtrate was concentrated. The concentrated residue triturated with heptane (1.5 L). The solids were filtered and dried and obtained 178 gr of Intermediate A. This reaction was performed as 196.0 g×1, and 200.0 g×1, using total of 396.0 g of compound 2. Yield: 178.0 g (83.4%).

Example 15. Synthesis of (1′R,2′R)-4-heptyl-5′-methyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-2,6-diol (Compound 14)

Process Description

To a stirred mixture of Intermediate A (82.0 g, 1.0 eq, 394.0 mmol) in toluene (3.5 L) was added (1S,4R)-1-methyl-4-(prop-1-en-2-yl)cyclohex-2-en-1-ol (65.9 g, 1.1 eq, 433.0 mmol) under nitrogen atmosphere at room temperature. Then the reaction mixture cooled to 0° C. and added PTSA (7.49 g, 0.1 eq, 39.4 mmol), and continued stirring for 20 mins at same temperature. TLC (20% ethyl acetate in heptane) confirms formation of product and some amount of starting material. LCMS also confirms the product formation ([C₂₃H₃₄O₂+H]⁺ [M+H]: 343.5) along with unwanted isomer. Quenched the reaction mixture at 0° C. with sat.aq. NaHCO₃. The mixture was diluted with ethyl acetate (500 mL), separated the layers, organic phase was washed with water (500 mL), brine (250 mL), dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure to get crude which was purified by combi-flash column (330 g) using heptane (0.5% triethylamine)/ethyl acetate as eluent. The pure product fractions were concentrated under reduced pressure, dried under high vacuum at rt for 16 h to get pure compound 14 (22.0 g, 16.3%) as grey color liquid.

Compound 14: FIG. 39 shows a ¹H NMR (CDCl₃) spectrum of Compound 14. ¹H NMR spectrum was obtained 25° C. on a Merc200-mercury300 spectrometer.

Example 16. Synthesis of (1R,2R)-4′-heptyl-2′,6′-dimethoxy-5-methyl-2-(prop-1-en-2-yl)-1,2,3,4-tetrahydro-1,1′-biphenyl (Compound 15)

To a stirring solution of Compound 14 (22.0 g, 1.0 eq, 64.2 mmol) in DMF (220 mL), K₂CO₃ (35.5 g, 4.0 eq, 257.0 mmol) was added at 0° C. Then MeI (40.37 g, 4.0 eq, 257.0 mmol) was added at 0° C. dropwise over a period of 10 min and the mixture was stirred for 30 mins at 0° C. The reaction mixture was stirred for overnight at room temperature. After completion of the reaction as indicated by TLC (10% ethyl acetate in heptane) and LCMS, the mixture was diluted with water (220 mL) extracted with ethyl acetate (2×220 mL). The organic phase was washed with water (220 mL), brine (110 mL), and dried over anhydrous sodium sulfate. The solids are filtered, and the filtrate was concentrated under reduced pressure to get crude which was purified by combi-flash column (330 g) using heptane (0.5% Et₃N)/ethyl acetate as eluent. The pure product fractions were pooled and concentrated under reduced pressure and dried under high vacuum for 16 h to get pure compound 15 (15 g, 63%) as light-yellow liquid.

Example 17. Synthesis of (1′R,2′R)-4-heptyl-6-methoxy-5′-methyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-2-ol (Compound 16)

7.2 Process Description

To a stirring solution of Thiol (20.6 g, 3.0 eq, 121.0 mmol) in DMF (300 mL), KOtBu (27.3 g, 6.0 eq, 243.0 mmol) was added in three portions under 5° C. After stirring 20 min at rt, compound 15 (15.0 g, 43.5 mmol) dissolved in DMF (120 mL) was added over a period of 10 min. The resulting reaction mixture was refluxed for 2.5 h. Completion of the reaction was indicated by TLC (10% ethyl acetate in heptane) and LCMS. The reaction mixture was cooled to 0-5° C., water (250 mL) and ethyl acetate (2-300 mL) was added. Organic layer was washed with cold water (3×200 mL), brine (2×200 mL), and dried over anhydrous sodium sulfate. The solids were filtered, and the filtrate was concentrated under reduced pressure to get crude mixture. The crude mixture was purified by combi-flash column (220 g) using heptane (0.5% Et₃N)/ethyl acetate as eluents. The pure product fractions were concentrated under reduced pressure, dried under high vacuum at rt for 16 h to get pure Compound 16 (9.0 g, 62%) as a light-yellow liquid.

Compound 16: FIG. 40 shows a ¹H NMR (CDCl₃) spectrum of Compound 16. ¹H NMR spectrum was obtained 25° C. on a Merc200-mercury300 spectrometer.

Example 18. Synthesis of (E)-2-(3,7-dimethylocta-2,6-dien-1-yl)-5-heptylbenzene-1,3-diol (Compound 17)

To a stirring solution of alumina (400.0 g, 16.0 eq, 3.92 mol) in DCE (250 mL), was added Intermediate A (50.0 g, 1.0 eq, 0.24 mol) and geraniol (24.0 g, 0.66 eq, 0.16 mol) was added at room temperature. The mixture was stirred for 6 hr. at reflux temperature. After completion of the reaction as indicated by TLC (10% ethyl acetate in heptane) and LCMS, the reaction mixture was filtered and the solids were washed with DCM (300 mL). The filtrate was washed with sat. aq. NaHCO₃ (500 mL) and with brine (250 mL) and dried over anhydrous sodium sulfate. The filtrate was concentrated under reduced pressure to get crude which was purified by combi-flash column (330 g) using heptane/ethyl acetate as eluent. The pure product fractions were concentrated under reduced pressure, dried under high vacuum at rt for 16 h to get pure Compound 17 as light brown solid.

Compound 17: FIG. 41 shows a ¹H NMR (CDCl₃) spectrum of Compound 17. ¹H NMR spectrum was obtained 25° C. on a Merc200-mercury300 spectrometer.

Example 19. Synthesis of (E)-2-(3,7-dimethylocta-2,6-dien-1-yl)-5-heptyl-1,3-dimethoxybenzene (Compound 18)

9.2 Process Description

To a stirring solution of Compound 17 (24.5 g, 1.0 eq, 71.11 mmol) in DMF (245 mL), K₂CO₃ (39.31 g, 4.0 eq, 284.4 mmol) was added at 0° C. Then MeI (40.37 g, 4.0 eq, 284.4 mmol) was added at 0° C. dropwise over a period of 10 min and the mixture was stirred for 30 mins at 0° C. The reaction mixture was stirred for overnight at room temperature. After completion of the reaction as indicated by TLC (10% ethyl acetate in heptane) and LCMS, the mixture was diluted with water (300 mL) extracted with ethyl acetate (2×250 mL). The organic phase was washed with water (300 mL), brine (100 mL), and dried over anhydrous sodium sulfate. The filtrate was concentrated under reduced pressure to get crude mixture which was purified by combi-flash column (330 g) using heptane/ethyl acetate as eluent. The pure product fractions were concentrated under reduced pressure, dried under high vacuum at rt for 16 h to get pure Compound 18 (14.0 g, 52.83%) as light yellow liquid.

Compound 18: FIG. 42 shows a ¹H NMR (CDCl₃) spectrum of Compound 18. ¹H NMR spectrum was obtained 25° C. on a Merc200-mercury300 spectrometer.

Example 20. Synthesis of (E)-2-(3,7-dimethylocta-2,6-dien-1-yl)-5-heptyl-3-methoxyphenol (Compound 19)

To a stirring solution of thiol (15.58 g, 3.0 eq, 91.79 mmol) in DMF (228 mL) KOtBu (20.60 g, 6.0 eq, 183.6 mmol) was added in three portions under 5° C. After stirring 20 min at rt, compound 18 (11.4 g, 30.6 mmol) dissolved in DMF (90 mL) was added at rt over a period of 10 min. The resulting reaction mixture was refluxed for 2.5 h. After completion of the reaction as indicated by TLC (10% ethyl acetate in heptane) and LCMS. The reaction mixture was cooled to 0-5° C., IN HCl (380 mL) was added to adjust pH ˜1. Water (200 mL) was added, extracted with ethyl acetate (500 mL), Organic layer was washed with cold water (2×250 mL), brine (300 mL), and dried over anhydrous sodium sulfate. The filtrate was concentrated under reduced pressure to get crude residue which was purified by combi-flash column (330 g) using heptane/ethyl acetate as eluent. The pure product fractions were concentrated under reduced pressure, dried under high vacuum at rt for 16 h to get pure Compound 19 as a pale-yellow oil.

Compound 19: FIG. 43 shows a ¹H NMR (CDCl₃) spectrum of Compound 19. ¹H NMR spectrum was obtained 25° C. on a Merc200-mercury300 spectrometer.

Example 21. Synthesis of (1′R,2′R)-6-methoxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-2-ol (Compound 3)

A 200 mL single neck round bottom flask was charged with CBD (5 g; 15.90 mmol) and K₂CO₃ (3.4 g; 23.84 mmol) and DMF (75 mL). The reaction mixture was stirred at room temperature for 30 min under nitrogen. CH₃I (2.71 g; 19.08 mmol) was added to the heterogeneous reaction mixture in 10 min. The reaction mixture was stirred at room temperature for 5 hours under nitrogen. The reaction was monitored by TLC (10⁰% Ethyl acetate+hexane). TLC shows 30-40% dimethoxy CBD, 25-30% Monomethoxy CBD and 20-25% CBD. Filtered the K₂CO₃ and washed with DMF (20.0 mL). The filtrate was added to the ice-cold water (200.0 mL) and was extracted with Ethyl acetate (100 mL). Ethyl acetate layer was washed with water (2×50 mL). Ethyl acetate layer was dried over Na₂SO₄ and concentrated to obtain 5.2 g of crude material.

Crude material column purification (ISCO) using 1-10% Ethyl acetate in Heptane. Pure fractions were concentrated to obtained 1.2 g Compound 3 (Monomethoxy CBD) as pale yellow oil.

Compound 3: FIG. 36 shows a ¹H NMR (CDCl₃) spectrum of Compound 3. ¹H NMR spectrum was obtained 25° C. on a Merc200-mercury300 spectrometer.

Example 22. PK and Time of Maximum Plasma (Tmax) for CBD and Compound 3 Objectives and Background

The purpose of this study was to determine the pharmacokinetics and time of maximum plasma (T_(max)) of the test articles (TA) CBD and Compound 3 following intraperitoneal (IP) administration to male C57BL/6 mice. This method of TA delivery, dose and mouse strain was to be used in a subsequent Pentylenetetrazol (PTZ) induced seizure model for the evaluation of the TA's for anti-epileptic activity.

Other compounds of the present disclosure (e.g., one or more compounds of Formula (I), (II), (III), Table 1 or Table 2) may also be evaluated in this assay.

Study Design N/ Dose Group Sex Test Article (mg/kg) Vehicle Route 1 27/ CBD 100 10% EOH/ IP M 10% Tween 80/ 80% Saline 2 27/ Compound 3 100 10% EOH/ IP M 10% Tween 80/ 80% Saline

Sample Collection Anti- Volume / Collection Times Group Matrix coagulant Time Point (h postdose) All Blood/ K₂EDTA ~1 mL 0,0.25, 0.5, 1, 1.5, Plasma (exsanguination) 2, 2.5, 4, and 24

Results Data description PK unit Group 1 Group 2 AUC(0-t) (obs ng-hr/ml 6834 30231 area) C_(Max) ng/ml 2727 21840 T_(Max) Minutes 15 & 60 30

Compound 3 clearly demonstrated improved bioavailability over CBD with plasma PK Area Under the Curve (AUC) calculation of over 4-fold greater and a C_(max) of 8-fold greater. CBD had two separate T_(max) peaks, we decided to use the later 60 minute time for PTZ studies as the overall blood plasma was more consistent at that timepoint.

Example 23 Receptor Binding Assay

Compounds of the present disclosure (e.g., one or more compounds of Formula (I), (I), (III), Table 1 or Table 2) may be tested for activity in receptor binding assays using methods known in the art, to evaluate agonist, antagonist, inverse agonist and other modes of activity. For example compounds of the disclosure may be tested in a adrenoceptor alpha 2A (ADRA2A) Agonist assay as follows:

cAMP Secondary Messenger Pathway Assay Overview

Cell lines stably expressing non-tagged adrenoceptor alpha 2A (ADRA2A) that signal through cAMP were used. Agonist assays monitored by the activation of ADRA2A via Gi or Gs secondary messenger signaling in a homogenous, non-imaging assay format using a technology called Enzyme Fragment Complementation (EFC) with β-galactosidase (β-Gal) as the functional reporter.

The enzyme is split into two complementary portions: EA for Enzyme Acceptor and ED for Enzyme Donor. ED is fused to cAMP and in the assay competes with cAMP generated by cells for binding to a cAMP-specific antibody. Active 1-Gal is formed by complementation of exogenous EA to any unbound ED cAMP. Active enzyme can then convert a chemiluminescent substrate, generating an output signal detectable on a standard microplate reader.

Cell Handling

1. cAMP assay ADRA2A cell lines were expanded from freezer stocks according to standard procedures. 2. Cells were seeded in a total volume of 20 μL into white walled, 384 well microplates and incubated at 37° C. for the appropriate time prior to testing 3. cAMP modulation was determined using the DiscoverX HitHunter cAMP XS+ assay

Gs Agonist Format

1. For agonist determination, cells were incubated with sample to induce response. 2. Media was aspirated from cells and replaced with 15 μL 2:1 HBSS/10 mM Hepes: cAMP XS+Ab reagent. 3. Intermediate dilution of sample stocks was performed to generate 4× sample in assay buffer. 4. 5 μL of 4× sample was added to cells and incubated at 37° C. or room temperature for 30 or 60 minutes. Vehicle concentration was 1%.

Gi Agonist Format

1. For agonist determination, cells were incubated with sample in the presence of EC80 forskolin to induce response. 2. Media was aspirated from cells and replaced with 15 μL 2:1 HBSS/10 mM Hepes: cAMP XS+Ab reagent. 3. Intermediate dilution of sample stocks was performed to generate 4× sample in assay buffer containing 4×EC80 forskolin. 4. 5 μL of 4× sample was added to cells and incubated at 37° C. or room temperature for 30 or 60 minutes. Final assay vehicle concentration was 1%

Signal Detection

1. After appropriate compound incubation, assay signal was generated through incubation with 20 μL cAMP XS+ED/CL lysis cocktail for one hour followed by incubation with 20 μL cAMP XS+EA reagent for three hours at room temperature. 2. Microplates were read following signal generation with a PerkinElmer Envision™ instrument for chemiluminescent signal detection.

Data Analysis

1. Compound activity was analyzed using CBIS data analysis suite (ChemInnovation, CA) 2. For Gs agonist mode assays, percentage activity is calculated using the following formula: % Activity=100%×(mean RLU of test sample−mean RLU of vehicle control)/(mean RLU of MAX control−mean RLU of vehicle control). 3. For Gi agonist mode assays, percentage activity is calculated using the following formula:

% Activity=100%×(1−(mean RLU of test sample−mean RLU of MAX control)/(mean RLU of vehicle control−mean RLU of MAX control))

Example 24. Effects of Compounds on LPS Stimulated Human PBMCs In Vitro

The effects of compounds of the present disclosure (e.g., one or more compounds of Formula (I), (II), (III), Table 1 or Table 2) on LPS Stimulated Human PBMCs in vitro can be tested using the following protocol.

Protocol

Three separate fresh blood samples (2×10 ml per donor) were acquired from ZenBio, shipped overnight NOT frozen. Upon receipt, cells were separated into 10 ml aliquots and mixed 3:1 with RBC lysis buffer for 15 min at Room Temp (RT). Cells were then washed 2× with sterile PBS and cells from the same donor then pooled and counted using a Luna FL cell counter to obtain viable nucleated cell counts using fluorescent dyes (Acridine Orange/Propidium Iodide). Cells were diluted to 2e6 cells/mi in Complete RPMI (RPMI+10% FBS+1×Pen/Strep/Glut) and 125 ul was added to each well of 96-well flat bottom plates. 125 ul of cRPMI containing each diluted test article (compounds of the disclosure) were added to the wells at time 0 h and briefly pipet mixed Cells were pre-treated for 1 h at 37 C/5% CO2. After 1 h cells were stimulated with 100 ng/ml LPS for an additional 24 h at 37 C/5% CO2. After a total of 25 h plates were spun down and supernatants harvested into a new 96 well plate and sealed using a foil adhesive seal and saved for Luminex cytokine analysis. Pelleted cells were moved into a new 96 deep well plates for Flow Cytometry Replicate wells will be combined into a single well for combined analysis.

Cell and Supernatant Harvest Outline Storage Type Process For Final Volume Condition Disposition Cells Cell +/- 250,000 Flow Stained for Flow Pellets cells Cytometry Super- Luminex 250 ul −80 C. Luminex natant Cytokine Analysis

Sample Analysis Analysis Sample/Tissue Flow Cytometry Human Analysis of different cell Phenotype PBMCs populations by Flow Cytometry. Three replicate wells pooled into a single Flow staining well. Milliplex Multiplex Cell Human Luminex 9plex: GM-CSF, HCYTOMAG-60K Supernatant IFN-γ, IL-10, IL-12p70, IL-17A/ CTLA8, IL-18, IL-1β, IL-6, TNF-α

Example 25. BioMap Diversity Plus Panel

Background on BioMAP technology platform

BioMAP panels consist of human primary cell-based systems designed to model different aspects of the human body in an in vitro format. The 12 systems in the Diversity PLUS panel allow test agent characterization in an unbiased way across a broad set of systems modeling various human disease states. BioMAP systems are constructed with one or more primary cell types from healthy human donors, with stimuli (such as cytokines or growth factors) added to capture relevant signaling networks that naturally occur in human tissue or pathological conditions. For example, systems that recapitulate aspects of the systemic immune response including monocyte-driven Th1 inflammation (LPS system) or Tcell stimulation (SAg system), chronic Th1 inflammation driven by macrophage activation (IMphg system) and the T cell-dependent activation of B cells that occurs in germinal centers (BT system). BioMAP is also used to predict toxicity profiles. Each test agent generates a signature BioMAP profile that is created from the changes in protein biomarker readouts within individual system environments. Biomarker readouts (7-17 per system) are selected for therapeutic and biological relevance, are predictive for disease outcomes or specific drug effects and are validated using agents with known mechanism of action (MoA). Each readout is measured quantitatively by immune-based methods that detect protein (e.g., ELISA) or functional assays that measure proliferation and viability. BioMAP readouts are diverse and include cell surface receptors, cytokines, chemokines, matrix molecules and enzymes.

Methods

Human primary cells in BioMAP systems are used at early passage (passage 4 or earlier) to minimize adaptation to cell culture conditions and preserve physiological signaling responses. All cells are from a pool of multiple donors (n=2-6), commercially purchased and handled according to the recommendations of the manufacturers. Human blood derived CD14+ monocytes are differentiated into macrophages in vitro before being added to the IMphg system. Abbreviations are used as follows: Human umbilical vein endothelial cells (HUVEC), Peripheral blood mononuclear cells (PBMC), Human neonatal dermal fibroblasts (HDFn), B cell receptor (BCR), T cell receptor (TCR) and Toll-like receptor (TLR). Cell types and stimuli used in each system are as follows: 3C system [HUVEC+(IL-1β, TNFα and IFNγ)], 4H system [HUVEC+(IL-4 and histamine)], LPS system [PBMC and HUVEC+LPS (TLR4 ligand)], SAg system [PBMC and HUVEC+TCR ligands], BT system [CD19+ B cells and PBMC+(α-IgM and TCR ligands)], BF4T system [bronchial epithelial cells and HDFn+(TNFα and IL-4)], BE3C system [bronchial epithelial cells+(IL-1β, TNFα and IFNγ)], CASM3C system [coronary artery smooth muscle cells+(IL-1β, TNFα and IFNγ)], HDF3CGF system [HDFn+(IL-10, TNFα, IFNγ, EGF, bFGF and PDGF-BB)], KF3CT system [keratinocytes and HDFn+(IL-1β, TNFα, IFNγ and TGFβ)], MyoF system [differentiated lung myofibroblasts+(TNFα and TGFβ)] and IMphg system [HUVEC and M1 macrophages+Zymosan (TLR2 ligand)]. Systems are derived from either single cell types or co-culture systems. Adherent cell types are cultured in 96 or 384-well plates until confluence, followed by the addition of PBMC (SAg and LPS systems). The BT system consists of CD19+ B cells co-cultured with PBMC and stimulated with a BCR activator and low levels of TCR stimulation. Test agents prepared in either DMSO (small molecules; final concentration ≤0.1%) or PBS (biologics) are added at the indicated concentrations 1-hr before stimulation, and remain in culture for 24-hrs or as otherwise indicated (48-hrs, MyoF system; 72-hrs, BT system (soluble readouts); 168-hrs, BT system (secreted IgG)). Each plate contains drug controls (e.g., legacy control test agent colchicine at 1.1 μM), negative controls (e.g., non-stimulated conditions) and vehicle controls (e.g., 0.1% DMSO) appropriate for each system. Direct ELISA is used to measure biomarker levels of cell-associated and cell membrane targets. Soluble factors from supernatants are quantified using either HTRF® detection, bead-based multiplex immunoassay or capture ELISA. Overt adverse effects of test agents on cell proliferation and viability (cytotoxicity) are detected by sulforhodamine B (SRB) staining, for adherent cells, and alamarBlue® reduction for cells in suspension. For proliferation assays, individual cell types are cultured at subconfluence and measured at time points optimized for each system (48-hrs: 3C and CASM3C systems; 72-hrs: BT and HDF3CGF systems; 96-hrs: SAg system). Cytotoxicity for adherent cells is measured by SRB (24-hrs: 3C, 4H, LPS, SAg, BF4T, BE3C, CASM3C, HDF3CGF, KF3CT, and IMphg systems; 48-hrs: MyoF system), and by alamarBlue staining for cells in suspension (24-hrs: SAg system; 42-hrs: BT system) at the time points indicated.

Results/Deliverables

A Profile plot which is an overlay of the BioMAP signature of four concentrations of a particular test agent. Significant biomarker readouts are annotated, and these key activities are classified and listed into biologically relevant categories. The Profile plot is followed by an overlay of one concentration of the test agent with one concentration of a selected Reference Benchmark. In this comparison, common or differentiating biomarker activities are annotated and listed by system, along with a description of the Reference Benchmark agent. Next, the test agent is mathematically compared against the BioMAP Reference Database to identify the top 3 agents with the most similar overall biomarker signature across the 12 systems. The top match is overlayed against the test agent with annotation of common biomarker activities, description of the similarity search result and the mathematical scores comparing the two profiles. If there are 3 or more test agents, a cluster analysis is performed using pairwise correlation analysis where test agents with similar profiles are graphically linked by lines. Lastly, test agents and consensus profiles for 19 predictive models that are based on profiles from multiple compounds in a known mechanism class are displayed in a Mechanism HeatMAP Analysis.

Embodiments

-   1. A method of treating a chronic inflammatory disease or mental     health disorder in a subject in need thereof, comprising     administering a compound of Formula (I), or a pharmaceutically     acceptable salt thereof

-   -   wherein:     -   R¹ and R³ are independently a hydrogen or alkyl; provided that         at least one of R¹ and R³ is alkyl;     -   R² is

-   -   R^(E) is hydroxy, halo, —NR^(A)R^(B), cyano, nitro, alkyl,         -haloalkyl, haloalkoxy and alkoxy;     -   R⁴, R^(4′), R⁵, R^(5′), R⁶, R^(6′), R⁷, R^(7′), R⁸, R^(8′), R⁹         are each independently selected from the group consisting of         hydrogen, —OH, alkyl, alkoxy, —NR^(A)R^(B), and halogen;     -   R^(A) and R^(B) are each independently hydrogen or -alkyl; and     -   n is 0, 1, or 2.

-   2. The method of embodiment 1, wherein R¹ is hydrogen and R³ is     alkyl.

-   3. The method of embodiment 2, wherein R¹ is hydrogen and R³ is     —C₁₋₆alkyl.

-   4. The method of embodiment 3, wherein R¹ is hydrogen and R³ is     methyl.

-   5. The method of embodiment 1, wherein R¹ and R³ are alkyl.

-   6. The method of embodiment 5, wherein R¹ and R³ are independently     —C₁₋₆alkyl.

-   7. The method of embodiment 6, wherein R¹ and R³ are methyl.

-   8. The method of any one of embodiments 1-7, wherein R² is

-   9. The method of any one of embodiments 1-8, R⁴, R^(4′), R⁵, R^(5′),     R⁶, R^(6′), R⁷, R^(7′), R⁸, R^(8′), R⁹ are each hydrogen. -   10. The method of any one of embodiments 1-9, wherein n is 0. -   11. The method of any one of embodiments 1-10, wherein the compound     is

-   12. The method of embodiment 11, wherein the compound is

-   13. The method of embodiment 11, wherein the compound is

-   14. The method of any one of embodiments 1-13, for treating a     chronic inflammatory disease. -   15. The method of embodiment 14, wherein the chronic inflammatory     disease is an inflammatory bowel disease (IBD). -   16. The method of embodiment 15, wherein the inflammatory bowel     disease is Crohn's disease. -   17. The method of embodiment 15, wherein the inflammatory bowel     disease is ulcerative colitis. -   18. The method of any one of embodiments 1-13, for treating a mental     health disorder. -   19. The method of embodiment 18, wherein the mental health disorder     is anxiety. -   20. The method of embodiment 18, wherein the mental health disorder     is schizophrenia. -   21. The method of any one of embodiments 1-20 wherein the subject is     human. -   22. A pharmaceutical composition comprising a compound of Formula     (I):

or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. 

1-40. (canceled)
 41. A pharmaceutical composition comprising the compound:

or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
 42. The pharmaceutical composition of claim 41, comprising:

and a pharmaceutically acceptable carrier.
 43. The pharmaceutical composition of claim 42, wherein the pharmaceutical composition is formulated for oral administration.
 44. A method of treating a chronic inflammatory disease in a subject in need thereof, the method comprising administering to the subject the pharmaceutical composition of claim 42, and a pharmaceutically acceptable carrier.
 45. The method of claim 44, wherein the chronic inflammatory disease is a inflammatory bowel disease.
 46. The method of claim 45, wherein the inflammatory bowel disease is Crohn's disease.
 47. The method of claim 45, wherein the inflammatory bowel disease is ulcerative colitis.
 48. The method of claim 44, wherein the composition is administered orally.
 49. A method of treating a chronic inflammatory disease in a subject in need thereof, the method comprising administering to the subject the compound:


50. The method of claim 49, wherein the chronic inflammatory disease is an inflammatory bowel disease.
 51. The method of claim 50, wherein the inflammatory bowel disease is Crohn's disease.
 52. The method of claim 50, wherein the inflammatory bowel disease is ulcerative colitis.
 53. The method of claim 49, wherein the compound is administered orally. 